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Drug—induced acute interstitial nephritis. fL. Teruel, F. Mampaso,
A. Gimenez, A. Gonzalo, J. Ortuno, Hospital Ramon Y Cajal, Madrid,
Spain. Fourteen cases of acute interstitial nephritis (AIN) induced by
different drugs (antibiotics, antiinfiammatory agents, diuretics) are
described. All of them had acute renal failure, dialysis being needed in
7 patients. In five cases with primary glomerulonephritis (3 IgA mesan-
gial, 2 acute) renal biopsy was performed because of acute and
unexplained renal function deterioration. One patient with the
hemolytic—uremic syndrome had associated AIN which was confirmed
by the presence of an intense interstitial infiltrate associated with the
vascular lesions. In the other 8 cases, renal biopsy was performed with
the clinical diagnosis of AIN, In 10 cases a monoclonal antibody study
of the infiltrate was undertaken. The infiltrate consisted mainly of T
lymphocytes (84 16%) with predominating cytotoxic—supressor pop-
ulation. Conclusions. Drug—induced AIN may constitute a superim-
posed event in the natural history of other nephropathies. Studies of the
cellular infiltrate support the theory of a cell—mediated immune reaction.
Azathioprine (AZ) and anti-lymphocyte globulin (ALG) indications in
renal transplanted (RT) patients immunosuppressed with cyclosporine
(CsA). J. Lloveras, X. Cuevas, M. Mir, A. Orfila, J.M. Puig, J. Aubia,
J. Masramon, Hospital G.M.D. L'Esperanca, Barcelona, Spain. Since
the introduction of CsA the indications for Az and ALG are controver-
sial. All our RT initially received CsA 14 mg/kg/day the first week that
was reduced to 2 mg/kg per week until maintenance doses between 4
and 6 mg/kg/day adjusted to CsA blood levels and nephrotoxicity. This
regime was administered either to patients that present acute tubular
necrosis (ATN) or not. In case ATN was prolonged more than 4 weeks,
we reduced CsA doses from 8 mg/kg/day to 4 mg/kg/day during the fifth
week and introduced Aza (2 mg/kg/day). If ATN persisted we reduced
CsA up to 2 mg/kg/day during the sixth week but we did not discontinue
CsA. Once renal function was reasumed (serum creatinine < 3.5 mg/dl)
we increased CsA progressively up to blood levels =500 ng/ml and we
discontinued Aza. Eight RT of the 75 RT treated with CsA received
Aza. Mean duration of ATN in these 8 RT was 67 days (55—80 days).
None of them has presented rejection episodes during the combined
therapy. All 8 RT have the graft functioning, although with higher
serum creatinines at 3 m, 6 m and 12 m, respectively, those RT did not
show ATN or did for less than 30 days. We indicate ALG in case of
acute severe vascular rejection, in highly sensitized RT or second grafts
that present acute rejection while they receive high doses of
corticosteroids (that we administer prophilactically in such patients
during the first 3 weeks), and in RT showing corticorresistent rejections
(biopsy proved). Eight RT of the 75 RT treated with CsA received ALG
in addition. Patient survival is 100%. Six of the 8 RT resolved the
rejection episode and have the graft functioning. One year graft survival
of the 75 RT treated with CsA is 87.5%. We conlude: (1.) In prolonged
ATN, the association of AZ to very low doses of CsA prevents rejection
and reduces nephrotoxicity. (2) ALG is effective in the forementioned
indications and we believe that it is not necessary to enlarge its
indications in order to achieve good graft survival rates.
Cyclosporlne (CsA) interactions with other drugs in renal transplanta-
tion (RT). A. Orfila, J. Lloveras, M. Mir, X. Cuevas, J. Aubia, J.
Masramon, Hospital G.M.D. L'Esperanca, Barcelona, Spain. The
association of some drugs to the administration of CsA may enhance
CsA nephrotoxicity by sinergism of the mechanisms of the toxic
activity, or by interference of the CsA pharmacokinetics either by
induction of the hepatic cytochrome P-450 enzymatic activity and
consequently increasing the CsA clearence or by inhibition of its
activity and consequently increasing the CsA blood levels and enhanc-
ing its nephrotoxicity. Aminoglicosides, Amphotericin B and Co-
trimoxazole may enhance the nephrotoxicity due to an additive effect.
We present 4 patients treated with Tobradistin, 3 with Amphotericin B
and 3 with Co-tnmoxazole. All except 2 patients (that received
Tobradistin) showed a significant increase of the serum creatinine that
returned to previous values after discontinuation of the forementioned
drugs. Rifampicin induces the enzymatic activity of P-450, 3 RT
received Rifampicin. One RT showed a sharp reduction of CsA blood
levels that was accompanied by a reversible acute rejection. In the
remaining 2 RT we doubled the CsA dose and the CsA blood levels
remained stable to previous values. Ketoconazol, Erithromycine and
high doses of steroids increase CsA blood levels. Four patients received
Ketoconazole and all of them showed an increase of the CsA blood
levels and serum creatinine. Three other patients received
Erithromycine and their CsA blood levels did not show any increase
because we simultaneously reduced the previous CsA dosage by two
thirds. We conclude: (1.) Avoid whenever possible the administration
of nephrotoxic drugs. (2.) Adjust CsA dosage according to the effect of
the associated drug on CsA blood levels in order to maintain previous
CsA blood levels and avoid nephrotoxicity or rejection. (3.) Frequently
monitor CsA blood levels.
Neoplasms on dialysis patients. Correlation of the incidence with the
time on the program E. Riambau, J. Roma, J. Aubia, J. Lloveras, J.
Masramon, f.M. Mallfre, E. Rius, J. Torrents, Hospital Gral. Mollet,
Hospital Gral. MD 1 Esperanca, Barcelona, Hospital Creu Roja,
Barcelona, Hospital Sta. Tecla, Tarragona, Hospital Mutua
igualadina, Spain. In order to determine whether the length of time of
permanence on dialysis program has any influence on the observed
increased incidence of neoplasms regarding its expected incidence in
patients on dialysis, we studied 538 of such patients during an 8 year
period (sex: 287 males, 251 females; age: 56.79 years; time period on
dialysis: 48.1 months). We distributed our population according to the
different periods of time of permanence on dialysis and established the
expected number of neoplasms for groups of non-uremic Spanish
general population matched with our studied dialysis patients for age,
sex and exposure time at risk by means of the calculation of the type
incidence. We excluded from our results the malignancies diagnosed
within the first three months on dialysis, those diagnosed in patients
previously treated with immunosuppressors and those with skin neo-
plasms. Eighteen neoplasms were diagnosed in the 538 studied patients
(sex: 12 males, 6 females; age: 59.8 years; time period on dialysis: 44.0
months). A decreased correlation between the relative risk of neoplasm
appearance and the period of time of permanence on dialysis was
observed (r =
—0.77;P < 0.01). Conclusions. (1.) The highest incidence
of neoplasms in patients on dialysis program appears during the first
year of treatment. (2.) The relative risk of neoplasm appearance
decreases according to the period of time of permanence on dialysis.
Immunosuppressive efficacy of low doses of cyclosporine (CI),
azathioprine (AZA) and prednisone (P in renal transplantation. L.
Pallardo, J. Sanchez, J. Garcia, C. Calvo, P. Antonio, R. Moreno,
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J.M. Cruz, Servicio de Nefrologia, Hospital General La Fe, Valencia,
Spain. We have analyzed the results obtained with CI (7 mg/kg), AZA
(1.5 mg/kg, stopping after two months) and P (30 mg) given to 33 renal
transplant patients (CAP group), comparing them with those of a group
of 45 patients treated with AZA and P, plus ATG in corticoresistant
acute rejection (AP group). Previous to transplant, there were no
significant differences in clinical and immunological parameters be-
tween the two groups. Results. The incidence of ATN (48% vs. 52%)
and its duration (10.8 3.4vs. 9.7 6.6days) were similar in CAP and
AP groups, respectively (P, NS). Acute rejection episodes were diag-
nosed in 11 CAP patients (33%), all corticosensitive, and in 38 AP
patients (84%) (P < 0.001), 35% of them being corticoresistant (P <
0.01). The hospital stay at discharge was 12.7 4.8 days in the CAP
group, and 24.3 13.6 days in the AP group (P < 0.001). The serum
creatinine at one month was 1.5 0.3 mg/dl in the CAP group and 2.3
1.2 mg/dl in the AP group (P < 0.001), with no significant differences
later. CI nephrotoxicity was a minor problem in the CAP group. The P
doses at one, three and six months were inferior in the CAP group (P <
0.001), as well as the incidence and severity of the infections. Actuarial
patient and graft survivals at six months were 100% and 91% in the CAP
group, and 98% and 80% in the AP group. In conclusion, low dose of
CI, associated to P and transitorily to AZA, are very effective prevent-
ing rejection, it simplifies the CI use, and the renal function is better
than those published with conventional protocols of CI.
LA V/HTL VIII (HIV) antibodies dialysis (D) and transplantation (TR).
J. Teixido, A. Caraips, E. Argelagues, R. Romero, J.M. Grino, R. Sola,
M.J. Ricart, F. Oppenheimer, E. Esteller, J. Martorell. *Hospital
General "Germans Trias I Pujol", Barcelona, Spain. Anti-HTLVIII
antibody was determined in 308 patients undergoing D or TR from 5
centers of the area of Barcelona. The partners of those found positive
were also studied. The method was ELISA (Abbot) confirmed by
immunofluorescence or Western blot. Of the patients, 92.5% had
received blood transfusions (x = 8 u.) and 3.6% had received plasma.
46.9% were treated by dialysis only, 44% had a functioning TR and
9.4% had an unsuccessful TR. Two patients were anti-HTLVIII +
(0.65%). The first one had been treated with plasmapheresis in 1983 and
he received 44 plasma u. and 24 blood u. from voluntary donors. At
least 11 patients dialyzed with the same D-monitors were HTLVIII
negative two years later. The second positive patient was transplanted
from a cadaveric donor who was a drug addict. Later on the recipient of
the other kidney from the same donor was studied and showed to be
positive. In both recipients the seroconversion was coincident with the
transplant. None of the three patients showed neither AIDS nor
AIDS-related complex symptoms, but all of them had disorders in
lymphocyte subpopulations. Among the 3 heterosexual partners, only
one was HTLV-III positive. We conclude that the HTLVIII positivity
in D and TR is related to infection mechanisms that can be prevented by
selection of the blood products and the kidney donors.
Renal function, hypertension and proteinuria in patients with solitary
kidneys. A. Gonzalo, R. Matesanz, J. Quintela, L. Orte, J. Ortuño,
Servicio de Nefrologla, Hospital Ramón y Cajal, Madrid, Spain. A
clinical study was performed in two groups of patients with solitary
kidneys. Group I had 14 patients (10 males and 4 females) aged between
8 and 73 years (x = 42) with unilateral renal agenesis. Group II had 40
patients (11 males and 29 females) with a single normal kidney at Ito 42
years after nephrectomy (Nx) for non-hypertensive unilateral renal
disease: 20 cases at Ito 10 years (x = 5) and 20 cases at 11 to 42 years(x = 19). Three patients in Group I had a significant impaired renal
function (Cr 1.8 and/Or Ccr < 60 mI/min/l.73 m2). Proteinuria(> 150
mg/24 hr) was present in four patients (28%) at 8 to 64 years in Group
I and in nine (22%) at 12 to 30 years post-Nx in Group II. De novo
diastolic hypertension developed in 50% (7 patients) in Group I and 35%
(14 patients) in Group II. The prevalence of hypertension was greater at
20 to 40 years in Group I and at 40 to 60 years in Group II, being
significantly higher than in the control population of the same age
group. There was no statistically significant relationship between pro-
teinuria, hypertension and impaired renal function. Our evaluation
indicates that impaired renal function occurs only in patients with
agenesis. The prevalence on hypertension and proteinuria was not
significantly different in both Groups, but hypertension developed at
earlier ages in patients with agenesis.
Microanalitic study in calcification front. S. Serrano, J. Aubia, LL.
Mañoso, J. Turd, A. Munné, J. Lloveras, J. Masramon, Hospital
G.M.D. L'Esperanca, Barcelona, Spain. To improve the sensitivity
and accuracy of methods to detect individual elements in bone, we have
compared the results of application of new techniques on bone biopsies
of dialyzed patients with aluminum deposits. The aim of this report is to
present the first findings of this study. Methods. (a.) Classical histology:
on undercalcified bone embedded with metil-metacrilate and conven-
tional tinctions of Pens and triauraxilic to determine Fe or Al deposits.
(b.) X-rays energy dispersive analysis (EDAX): applied on the same
biopsies, after desplastifling, and dessication using the critic—point
techniques. (c.) Secondary-ions rays spectrometry (SIMS): also on the
same biopsies, using liquid galium (39 Key 0: 500 A) and a quadripolar
sprectometer. Conclusions. The SIMS microanalysis appears to have a
higher resolution power and permits the simultaneous detection of
diverse metalic ions in the calcification front. The initial findings allow
us to conclude that SIMS and EDAX techniques application will
improve the conventional microscopy.
Neopterin blood levels (nN) in renal transplant recipients (RT). J.
Lloveras, X. Palazon, X. Cuevas, M. Mir, A. Orfila, I. Llorach, J.
Aubia, J. Masramon, Hospital G.M.D. L'Esperanca, Barcelona,
Spain. We determined nN values in 30 healthy individuals aged 18 to 55
years. The nN values were: 2.9 1.5 nmol/liter. nN values were also
determined in 23 adult patients on dialysis program, included in waiting
list for transplantation, free from infection or neoplasm. Their average
nN values were: 153 47 nmol/liter. We made 184 nN determinations
in 20 RT aged 15 to 56 years old. In 8 RT that did not require dialysis,
a minimum of three nN were determined during the first 30 days
post-RT (without rejection) observing a progessive decrease in all them
with regard to the nN previous to the RT (: 22.1 9.1 nmol/liter at day
30 post-RT). In 10 RT nN were determined the patients being in
"stable" condition more than 30 days post-RT, post-rejection or
post-CMV infection: : 30.3 10.9 nmol/liter. nN were also determined
between 1 and 4 days after diagnosis of 12 rejection episodes (biopsy
proved) in 9 RT. In all cases significant increments were observed
regarding respective previous nN: , 168 66.4 nmol/liter. Between 7
and 15 days after rejection treatment, those that respond to treatment
show a fast decrease to : 27.3 7.8 nmol/liter. In 3 RT with CMV
infection diagnosed by hemoculture, nN increased regarding the respec-
tive previous values 110, 220 and 280 nmol/liter, respectively. In one RT
with bronchial adenocarcinoma nN ranged between 6 and 14 nmollliter.
Another RT with Legionella Pneumonia registered nN between 140 and
185 nmol/liter. Another RT presenting Salmonella Enteritidis registered
nN between 120 to 220 nmol/liter. Another RI during a lupus
erithomatosis episode registered nN between 80 and 130 nmollliter. We
conclude: nN are low in healthy individuals, are high in dialysis patients
and rapidly decrease after a functioning RI. nN are low in "stable"
condition of the patients and significatively increase with rejection
episodes, decreasing again after its resolution. nN increase with CMV
infections, in other severe infections and in lupus episodes.
Idiopathic hypercalciunia in infancy: Study of 25 cases. M. Vdz-
quez—Martul, E. Villa, J,L. Ecija, M. Sanchez Bayle, A. Sonseca, M.E.
Martinez, Nephrology Section. Hospital Niño Jesds and S. Biochem-
istry, C.S. La Paz, Madrid, Spain. We define hypercalciuria (HC) as
values above 4 mg/kg/day under a normal diet. We studied the signifi-
cance of other parameters as the calcium/creatinine (Ca/Cr) quotient
and the calcium excretion per 100 ml of glomerular filtrate (E CalIOO
Fg). Our protocol (PAK's modified) studied 3 situations: normal and
restrictive diets of 800 and 400 mg of Ca/l .73 m2/day, respectively, and
the third on oral overload of Ca 1 g/l .73 m2. The PTH was measured
after a fasting period and previous the oral Ca overload. Of the 25 cases
12 were female, and 13 male, age 8.7 2.7. The study included 16
children at random and 15 siblings. Twenty—four children had absortive
hypercalciuria (AHC) 6.18 2.26 mg/kg/day, 8 had normal calciuria
with the restrictive diet, 3.04 0.47 being diagnosed absortive HC type
II; 16 Rept HC with the restrictive diet, 5.93 1.31. In 6 HC persisted
even in fasting condition, being defined as absortive HC type I, since all
had normal PTH values of 2.5 0.58. We found only 1 case of renal
hypercalciuria (RHC), 5.1 mg/kg/day, which was maintained in all
situations and with elevated PTH values. All had normal magnesiuria
except 1 case. Forty percent of siblings had HC. Of the parameters
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evaluated to define HC, none was more valuable, the three must be
considered. An elevation of the fasting PTH level is essential for the
diagnosis of RHC. The oral Ca overload was non-diagnostic in 18%
cases. AHC predominated over RHC and AHC type I over AHC type II.
Renal involvement In essential mixed cryoglobulinemia (EMC). J.
Madrenas, M, Vallés, F. Garcia—Bra gado, L, Piera, Services of
Nephrology and Internal Medicine, Hospital General 'Tall d'
Hebrón", Universitat Autônoma, Barcelona, Spain. In our series of 18
patients with EMC, 10 (55.5%) presented renal involvement. Nine had
EMC type II and 1 type III. Mean age was 56. In addition to renal
involvement, the mean of organs affected was 4.2. Eight patients had
renal disease at the time of diagnosis (hypertension, 6; nephrotic
syndrome, 4; asymptomatic urinary abnormalities, 3; acute nephritic
syndrome, 2; isolated proteinuria, 1; renal failure (serum creatinine 1.5
mg/dl), 2 (other 5 patients had decrease of creatinine clearance).
Cryocrite before treatment oscillate to 8.5%. The mean levels of C3,
C4, and C3PA were 67.1, 6.9 and 27.2 mg/dl, respectively. The clinical
and laboratory data of these 10 patients were compared to those of
remaining 8 patients without renal involvement. Significantly lower
values of C4 in patients with EMC and renal involvement were detected(P = 0.022). Renal histologic picture was consistent with mesangi-
ocapillary glomerulonephritis in all cases. Renal vasculitis was detected
only in 1 case. All patients received 6 methyl-prednisolone (1 mg/
kg/day). Cyclophosphamide was added in 8 and plasmapheresis in 4. A
decrease of cryocrite levels was achieved in 7 patients. Renal function
improved in 2 cases but urinary abnormalities persisted in 8. Two
patients died during the first episode of renal disease. After a 4-½ year
follow—up, 4 patients developed progressive renal failure.
Malignant hypertension: clinical data, prognostic factors and treat-
ment. F. EscuIn, M. Perrez Fontan, E. Huarte, J.L. Miguel, R. Selgas,
A. Torre y L. Sanchez Sicilia. Servicio de Nefrolog(a, C.S. La Paz,
Madrid, Spain. We have retrospectively reviewed in the last four years
29 malignant hypertensive patients (pts): antecedents, clinical data
before and during hospital stay, treatment and results, and possible
prognostic factors. Inclusion criteria were: diastolic blood pressure
over 130 mm Hg, hypertensive retinopathy degree III—IV and renal
failure (serum creatinine over 1.7 mg/dl). Blood pressure (BP) at
hospital admission ranged between 170 and 290 mm Hg for systolic and
130 to 180 for diastolic; mean values were respectively: 230.4
30.3/144 14.7 mm Hg. Blood pressure control was only properly
reached during the first hours in 20 cases (69%). In 3 patients (10.3%)
BP control was not complete during the first days. In other 6 cases this
control was not reached at all. Treatment success rate reached 100%
only when both nitroprusside and dialysis were used; threefold or
fourfold therapy was successful in 80% of the pts. As previously
known, renal function at hospital admission was the main prognostic
factor. So, those pts with serum creatinine lower than 4 mg/dl (N = 12)
maintained or even increased their renal function. Among these pts with
creatinine between 4 and 7 mg/dl (N = 6), three did need hemodialysis
treatment, two temporarily and 1 indefinitely. Among pts with creati-
nine higher than 7 mg/dl (N = 11), only one did not receive hemodial-
ysis, 9 were included in chronic dialysis program and another one
needed dialysis only temporarily.
Hypertension in focal segmental glomerulosclerosis (FSGS). Clinico-
Histological Correlation. L. Orofino, C. Quereda, S. Lamas, R. Marcén,
A. Gonzalo, J. Ortuno, Servicio de NefrologIa, Hospital Ramón y
Cajal, Madrid, Spain. Prevalence of hypertension in 288 patients with
primary chronic glomerulonephritis (GN) was 23.3% vs. 12.8% found in
a control group of 3477 subjects of the same geographic area, P < 0.01.
Hypertension was more frequent in FSGS (43%), than in the rest of GN
(19.8%), P < 0.01. When patients with normal renal function were
considered, prevalence of hypertension (12.7%) was similar to that of
the control group, except in FSGS (31%) P < 0.05. In a double—blind
clinico-pathological study of the 42 patients with FSGS followed during
36 months (6—86), 14 had nephrotic syndrome (11 adults and 3 children),
18 were hypertensive (17 adults and 1 child) and 7 (6 adults and 1 child),
had altered renal function. Hypertension was less frequent in patients
with nephrotic syndrome, P < 0.02, and there was an association
between hypertension and both glomerular sclerosis and interstitial cell
proliferation, P < 0.05. The presence of more than 20% of segmental
sclerosis and interstitial cell proliferation were bad prognostic signs, P
<0.01 and P < 0.05. Conclusions. (1.) Hypertension is more frequent
in FSGS than in other GN, both in patients with normal and impaired
renal function, especially in adults without the nephrotic syndrome. (2.)
Glomerular sclerosis and interstitial cell proliferation are associated
with hypertension and poor prognosis. (3.) FSGS includes an hetero-
geneous group of entities with similar histologic appearance.
Focal and segmental glomerulosclerosis (FSGS) in a kidney graft:
Hyperfiltration hypothesis confirmed. E. Huarte, M.L. Picazo, A. Sanz,
R. Selgas, L.S. Sicilia, Hospital La Paz, Madrid, Spain. Reduced renal
mass and subsequent hyperfiltration degenerates to FSGS. We show a
patient who confirms this fact. He was 41 years old; 12 years were spent
under hemodialysis treatment because of chronic glomerulonephritis.
He received a cadaver graft from a donor 5 years old with 2 HLA
identities. Its main renal artery was divided in two branches before the
kidney hilium. No immediate complications were presented; Ccr at 4th
month was 52 mI/mm, with no proteinuria nor hypertension. At 5th
month, he developed hypertension, proteinuria (3.25 g/24 hE) and
obstructive lymphocele. Lower pole graft was biopsied showing FSGS.
At 6th month an intraperitoneal marsupialization was performed; pro-
teinuria reached nephrotic range, Ccr was 50 mI/mm and hypertension
persisted. At 20th month, he developed fever, decreasing in Ccr, and
Cytomegalovirus and Toxoplasma Infections. Urogram did not show
obstruction. Arteriography features were: upper renal arery stenosis
with normal peripheral vascularization and a large lower pole with poor
peripheral vascularization. One month after, transplantation was per-
formed with the following features:: lower pole (upper in receptor and
renal arery stenosis) was micro- and macroscopically normal except for
juxtaglomerular hypertrophy compatible with chronic ischemia; upper
pole (normal artery) was hypertrophic and showed FSGS with
hyalinosis, tubular compensatory hypertrophy and diffuse deposits of
1gM and C3, all of them compatible with hyperfiltration nephropathy. In
conclusion we confirm the hyperfiltration hypothesis because the lower
pole was protected from it through its branch artery stenosis. Probably
this situation could be peculiar in children renal grafts transplanted to
adults in similar conditions.
Drug induced acute tubulointerstitial nephrltis. A.M. Castelao, S.
Gil—Vernet, R. Poveda, M. Carrera, J. Alsina, Hospital de Bellvitge,
Barcelona, Spain. Acute tubulointerstitial nephritis (ATIN) due to
drugs is not a very frequent cause of acute renal failure in our country
(0.7% of all cases in our hospital). Nevertheless it is suspected to be the
cause of more cases without having been proved in the diagnosis. In a
period of 8 years we have detected 7 patients with ATIN: 4 males and
3 females, aged between 46 and 72, (it 58 9.7). Drugs responsible were
rifampicin (3), indomethacin (1), triamterene (1), chlorothiazide (1) and
alopurinol (1). Three patients had suffered previous renal failure.
Clinical syndrome appeared with general status impairment (6), digstive
disturbances (6), skin rash (5), fever (4), lumbar pain (2), dark urine (1)
and various other hematologic disturbances. All patients presented
ARF, being oliguric in 4. Urinary sediment was abnormal in all cases
and the proteinuria oscillated from 0.55 to 8.4 g/day. Histopathological
findings in 5 cases were consistent with the diagnosis of ATIN. In a
patient with ATIN due to rifampicin, the immunofluorescence study
revealed the presence of Ig Gin the interstitium and tubular membrane.
Five patients needed dialysis. In all them renal function was retored to
its previous level. In the case of ATIN due to indomethacin, an
abdominal syntiphotography with gallium citrate (67 Ga) revealed
uptake by both kidneys. In summary, symptoms may subside on
discontinuing the administration of the drug if an early diagnosis is
made, and in some instances, although it can be disputed, prednisone
can reduce the chronic residual kidney damage.
Renal transplantation (RT) in diabetic patients. J. Lloveras, A. Orfila,
F. Cano, M. Mir, X. Cuevas, I. Llorach, J. Aubia, J. Masramón,
Hospital G.M.D. L'Esperanca, Barcelona, Spain. One hundred and
twenty—three consecutive RT have been performed in 115 patients.
Eight recipients were diabetics: 6 males and 2 females, average 39.6
years (30—56 y). Follow—up was 3 to 38 months (it 22.2 months). Period
of time on dialysis was 9 to 36 months (it 22.5 months). Interval of time
between diagnosis of diabetes and RT was 10 months to 28 years (it 13.2
y). Three of the 8 RT simultaneously received a pancreatic graft, (PT)
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2 segmental and 1 whole organ, all with urinary diversion. All 3 PT were
removed within the 30 day post-TP due to infected exocrine leakage in
two (with functioning PT) and to venous thrombosis in the third. One of
the 3 died 45 days later due to sepsis secondary to the infected leak and
is the only death of the 8 RT. Two RT received azathioprine and 6
cyclosporine. All kidney grafts have good renal function except one that
lost the graft due to acute vascular rejection at day 45. Six of the 8 RT
presented peripheral polyneuropathy that partially improved after RT.
Five of the RT presented bilateral and 1 unilateral amaurosis prior to
RT. The remaining 2 showed microaneneurisms and microhemorrh-
ages. Three of the 6 with functioning grafts have suffered multiple
amputations post-RT. Three RT have developed multiple vascular
calcifications. One RT aortic aneurism and 1 RT transient cerebro-
vascular accident post-RT. Four RT presented fungal urinary infec-
tions. Days of hospitalization before RT were 14, 30 and 47 in 3 patients
in 3, 9 and 17 months of CAPD treatment, respectively. The remaining
5 patients (all on hemodialysis) did not have hospitalizations prior to
RT. Rehospitalization post-RT was: 5 RT from 1 to 3 times with a total
between 4 days and 30 days. Another RT 6 times (405 days). All need
higher insulin doses than before RT. We conclude: 1 year graft and
patient survival is comparable to non-diabetic RTs. The most severe
complications are those derived from vasculopathy.
Ten years of integrated treatement with dialysis of diabetic patients. F.
Coronel, L. Hortal, P. Horcajo, P. Naranjo, C. del Pozo, J. Torrente,
A. Barrientos, Servicio de Nefrologia del Hospital Clinico de San
Carlos, Madrid, Spain. We describe ten years of experience with
diabetic patients treated with three different dialysis methods, hemodi-
alysis (HD), intermittent peritoneal dialysis (IPD) and continuous
ambulatory peritoneal dialysis (CAPD), changing from one to another
technique in relation with the clinical situation and compliance of the
patients. From October 1976 to May 1986 we studied 55 patients.
Twenty—four of them were treated only with CAPD, 15 with HD and 6
with IPD. The remaining 10 were maintained on a combination of two
or three dialysis methods. The cumulative experience of 33 patients on
CAPD was 644 months with a mean of 19.5 14.3. On HD were treated
24 patients, total experience of 529 months and a mean rate of 22
20.7. The experience of IPD was 107 months (11.9 6) in 9 patients.
Age, duration of diabetes and residual renal function were similar in the
three groups. The hospitalization rate (days of hospitalization/year) was
32.3 39 on CAPD; peritonitis was the most frequent cause (54.8%), in
second place the cardiovascular (14.4%) and gastrointestinal problems
(10.5%). In HD the hospitalization rate was 24.7 32.6 days/year; the
vascular—access complications amount to 34% of the hospitalization,
afterward cardiovascular problems (20.4%) and finally hypertension
(11.3%). Peritonitis (45%), vascular complications (15%) and metabolic
derangements (15%) were the most frequent causes of hospitalization of
IPD, with a mean rate of 88 + 84. The patient survival on CAPD was
92% in the first year, 79% the second and 64% the third and fourth
years. The survival on HD was 90% the first year, 80% the second, 48%
the third and 36% the fourth year. Only 63% survived on IPD the first
year and the 12% at 18 months. The technique survival rates were 85%,
66%, 60% and 51% in the 1st, 2nd, 3rd and 4th year on CAPD. The rate
for maintenance on HD was 84%, 75%, 46%, and 34% for the same
period. On IPD the rates of dialysis continuation were 55% the first year
and 11% at 18 months. The best control of sugar in blood and blood
prssure control were obtained with CAPD. We conclude that the
intergrated treatment with CAPD and HD can offer a good survival for
the diabetic patients, the former with better survival in the long—term
follow—up and the latter with lower hospitalization rate. Prevention of
peritonitis and better surgical techniques in angio-access can drop the
high morbidity.
Comparison of CAPD versus hemodialysis (HD) results in diabetics
treated in the same center. J. Aubia, L. Hojman, M. Chine, J.M. Puig,
I. Llorach, M. Cuxart, J. Lloveras, J. Masaramon, Hospital G.M.D.
L'Esperanca, Barcelona, Spain. CAPD has been suggested as the
elective treatment in diabetic patients with CRF; however the few
reports comparing CAPD with HD results in diabetics obtained in the
same institution and simultaneous is striking. We analyzed the reports
of our diabetic patients from 80/08 to 85/10: 22 patients began CAPD
and 26 HD, Clinical and biological data of both groups and their
evolution are compared, as well as diabetic complications (visual,
vascular), mortality, morbidity and rehabilitation in both groups. Re-
sults. In agreement with our aim of offering CAPD or HD as a real
free—choice, the demographic characteristics of both groups were: age,
59.3 9.9 and 50.9 4.4, sex rn/f, 11/11, 17/9); duration of nephrop-
athy; type of diabetes (1/lI: 10/12, 13/13). Vascular and nutrition status
and the presence of diabetic complications were similar at the beginning
of treatment. Actuarial survival in CAPD at 24 moths was 33.65% and
65.44% in HD. The morbidity measured by hospitalization days/year/
patient was 28.18 20.6 and 12.69 19.04 days, respectively. Both of
these figures are statistically significantly different. The most frequent
cause of hospitalization has been peritonitis in CAPD and ischemic or
infectious complications in HD. Amputations predominated in the HD
group. Neither access problem or glycemic regulation represented
serious problems in HD. Hematocrit values were higher (28.45 9.7
and 26.7 7.2) and albumin lower (32.74 16, 47.9 10.4) in CAPD
and no differences were found in Ca, P04, FA or PTH. When the CAPD
morbidity figures were analyzed in relation to time, a significant
decrease in peritonitis hospitalization was disclosed: 34.3 days/patient
in the initial period to 11.6 days in the 83—85 period. Conclusion. The
objective results of CAPD have been inferior with respect to HD due to
the initial high incidence of peritonitis in this time. Now, according to
the progressive improvements in this field both treatments tend to be
closely similar in results.
Paired filtration dialysis with the two chamber technique (PFD-TCT).
J. Botella, P.M. Ghezzi, P. Zucchelli, S. Ringoir, C. Sanz—Moreno, S.
Nigrelli, A. Santoro, R. Vanholder, Renal Departments of Madrid,
Spain, Cuneo and Bologna, Italy, and Ghent, Belgium. In order to
reduce dialysis time it is possible to use hediafiltration, but on carrying
out diffusion (D) and convection (C) simultaneously in this technique,
there is a mutually negative influence. The Khdf is lower than the sum of
K and Kd if both C and D were carried out separately. In order to solve
this contradiction a hollow fiber dialyzer with two on line but indepen-
dent chambers was designed; in the first chamber made of polysulfone,
0.4 sq.m. and no dialysate, C is carried out; in the second chamber
made of cuprophan, 1.1 sq.m., D is carried out. The following results
have been obtained with this technique: in vitro, Kbun 241 11, Kcr 207
12, K,, 169 15, Kb12 82 2. Short term data are: schema, 3 hours,
3 times a week; Q,, <300 mi/mn; Qd 500 mI/mn; total UF = 10% body
weight; 8 patients. Results. Kt/V 0.99 0.1; midweek BUN 86 15,
TAC 57 12; pcr 1.2 0.1. Long term data. Over 6 months 26 patients
were transferred from HD (12 hr/week) to PFD-TCT (9 hr/week). Good
intra- and interdialysis tolerance was obtained and there were no
statistically significant changes in the clinical and biochemical parame-
ters. In conclusion: PFD-TCT is a technique which allows a reduction
of dialysis time from 12 to 9 hours per week.
Elastase release in hemodialysis (HD). A study of its correlation with
leukopenia and anaphylotoxin CSa. J. Bonal, M.C. Pastor, J. TeixidO,
R. Romero, J. Bonet, R. Lauzurica, A. Serra, A. Caralps, A.
Corominas, Hospital General 'Germans Trias I Pujol", Barcelona,
Spain. Leukopenia induced in hemodialysis has been related to the
activation of complement. On the other hand, anaphylotoxin C5a has
been shown to be a stimulus for the release of granulocyte elastase. We
have examined the relationship between C5a generation, elastase
release and leukopenia in patients on hemodialysis. Six stable patients
on hemodialysis were sequentially exposed to membranes with
cuproammonium (CU), ethylenevinyl alochol (EVAL), hemophan (HE)
and polyacrylonitrile (AN-69). Leukocyte counts, C5a serum levels (by
radioimmunoassay) and elastase levels (by enzyme immunoassay),
were measured in samples taken at 0 and 15 minutes at the inlet and at
the outlet of the dialyzer. The results are expressed as means and
correlated by statistical methods (linear regression analysis and
Spearman's test). Results at 15 minutes in %
Leukocytes C5a Generation Elastase Release
CU
—69 +402 +15
EVAL —47 +101 +28
HE —14 +27 +9
AN-69 — 2 + 10 +38
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No significant correlation was found in any of the dialyer membranes
tested, between elastase release, C5a generation and induced
leukopenia. Our results indicate that other factors than anaphylotoxin
and leukopenia are related to the release of granulocyte elastase
(frustrated phagocytosis ?).
Treatment with desferrioxamine (DFO) of normochromic and
normocytic anemia of hemodialysis (lID) patients. M. Praga, A. Andrés,
J. Nieto, J.M. Morales, L.M. Ruilope, V. Gutiérrez Millet, J.M.
Alcázar, J.L. Rodicio, Hospital "1° de Octubre", Madrid, Spain. We
have prospectively investigated the effect of DFO adminstration (2
grams i.v. after every HD session during six months) on the normocytic
and normochromic anemia of 7 HD patients with elevated blood
transfusion requirements. None of them had neither clinical nor ana-
lytical data of chromic aluminium (AL) intoxication. The basal levels of
serum AL oscillated between 38 and 106 iliter (x 83 25 pg/liter) and
did not increase significantly after the first dose of DFO. At the end of
DFO treatment, the hematocrit had increased from 20.5 2.7% to 30.4
7.7% (P < 0.005) and the transfusional needings decreased from 3.5
2.2 units in the six months prior to DFO, to 0.7 0.9 units during
DFO adminstration. No patient required blood transfusions during the
second half of DFO therapy period. The serum ferritin fell from 2649
1331 ng/ml to 1268 1008 ng/ml (P < 0.025) and the serum AL
decreased to 48 11 pg/liter at the end of DFO administration (P <
0.01). No significant change was observed in MCV, MCH, reticulocyte
count, white blood cells nor platelet count. Two months after DFO
withdrawal the hematocrit value fell significantly to 22.2 1.6% (P <
0.01). DFO therapy was restarted in one patient at a lower dose (1 gram
i.v. after every HD session) and an increase of hematocrit from 23.2 to
40,2 was again observed after three months of treatment. The tolerance
to DFO was excellent. We conclude that DFO therapy can be consid-
ered in HD patients with severe anemia and elevated blood transfusion
requirements.
Nisoldipine (N) and the renal management of sodium in essential
hypertension. B. Miranda, L.M. Ruilope, R. Garcia Robles, J.M.
Alcázar, S. Mateo, C. Lumbreras, J. Sancho, J.L. Rodicio, Servicio de
Nefrologta Hospital J0 Octubre & Servicio Endocrinologla Hospital
RamOn y Cajal, Madrid, Spain. In order to assess the influence of
nisoldipine on the renal handling of sodium, the 24-hour urinary
excretion of sodium and the renal rsponse to an i.v. saline load (2000 ml
isotonic saline in 4 hours) were measured in a state of sodium repletion
(150 mEq/day) and depletion (20 mEq/day), both in normotensive
volunteers (V) and essential hypertensives (H) after a four day treat-
ment with placebo and nisoldipine (10 mg/day). We also measured the
variations of blood pressure, heart rate, plasma renin activity (PRA)
and plasma aldosterone (PA). In the two situations of sodium balance
studied, a sigificant increase of the 24-hour urinary excretion of sodium
was observed both in V and H (P < 0.01). In response to the saline load,
natriuresis also increased significantly after N (P < 0.01) independently
of the situation of sodium balance in the two groups studied. The BP
decreased significantly after N only in H (P < 0.01). The behavior of
PRA and PA seemed to differ between V and H. No variations were
observed after N in V while a tendency to lower levels of PRA was
observed in H during sodium depletion. We conclude that nisoldipine is
clearly natnuretic in normal volunteers and in essential hypertensives
even in the presence of a severe restriction of salt in the diet.
Sublingual nifedipine prevents the renal toxicity of radiographic con-
trast agents. L.M. Ruilope, B. Miranda, A. Oliet, J.M. Alcázar, 1.
Hernández, C. Lumbreras, S. Mateo, J.L. Rodicio, Department of
Nephrology, Hospital 1° Octubre, Madrid, Spain. A study has been
conducted in order to assess the hypothesis of a protective role of
calcium channel blocking agents on the renal toxicity induced by
radiocontrast media. A group of 20 patients receiving in a double—blind
fashion sublingual nifedipine (N) or placebo (P) were included in the
study. A renal arteriography was performed in every case, and the
presence of renal failure (serum creatinine> 1.5 mg/dl) or an advanced
age (above 70 years) increased the risk of appearance of renal damage.
Blood pressure (BP), creatinine clearance (CC) and 24-hour urinary
volume (UV) and excretion of sodium (naU), potassium (KU) and
N-acetyl-beta-d-glucosaminidase (NAG) were measured in three sepa-
rate occasions the day before, the day after and the day when the renal
angiography was performed. No variation was observed in BP, in N nor
in P treated groups. A significant decrement of CC was found after P (P
< 0.05) accompanied by a significant decrease of UV (P < 0.05) and
NaU (P < 0.05). The urinary excretion of NAG increased significantly
in P (P < 0.01) and N (P < 0.05), but with a significantly higher percent
change in P (P < 0.05). The tolerance of N and P was excellent. We
conclude that sublingual nifedipine exerts a protective effect on the
renal toxic effect of radiocontrast agents.
Cyclosporine (CyA) in minimal change nephrotlc syndrome (MCNS).
V. Gutierrez Millet, I. Bellow, A. Oliet, M. Praga, Hospital 10 Octubre,
Madrid, Spain. Three patients (one female and two males, ages ranging
from 14 to 58 years) with steroid sensitive and dependent MCNS
assessed by renal biopsy were treated with CyA. All had frequent
relapses and their steroid dependency had not been erradicated by
means of two courses of immunosuppressants (cyclophosphamide and
chlorambucil). The three patients were normotensive, had normal GFR
and their proteinuria ranged between 8 and 30 g/day, They were treated
with CyA without steroids at an initial dose ranging between 5 and 7.5
mg/kg/day and this dose thereafter was decreased progressively. Max-
imal blood levels of CyA ranging between 630 to 1090 ng/ml and
minimal levels between 85 to 140 ng/ml were achieved. Proteinuria
disappeared between days 64 and 69 of onset of CyA. Complete
remission of NS without relapses was maintained 6 months after onset
of therapy despite minimal CyA doses used (1.5 mg/kg/day). No
significant changes were induced by CyA in B and T lymphocyte
subset; policlonal response to PHA and PWM, nor clinical significant
side—effects were detected. Our experience suggests that CyA is a
useful drug for the therapy of patients with steroid sensitive and
dependent, frequently relapsing MCNS.
PAF-acether (platelet-activating factor) and biocompatibiity of hemo-
dialysis membranes. J. Madrenas, G. Pintos Morell, J. Bartolomé, E.
Pirotzky, J. Rey, J.A. Rodriguez, A. Olmos, J. Benveniste, L. Piera.
Department of Nephrology, Hospital General "VaIl d'Hebron",
Barcelona, Spain and INSERM U 200, Univ. Paris-Sud, 32 rue des
Carnets, 92140 Clamart, France. PAF-acether is a potent mediator of
inflammation and anaphylaxis. Intravenous injection of PAF-acether
into the rabbits induces neutropenia, hypotension and shock. Neutro-
penia and hypotension are two parameters frequently observed in
patients undergoing hemodialysis with cuprophan membranes. We
studied the release of PAF-acether in the venous blood of 3 patients
undergoing hemodialysis with cuprophan or with polyacrylonitrile
membranes (AN69.Hospal). Blood samples (2 ml) were collected from
the venous segment of the extracorporeal circuit at 0, 5, 15, and 240
minutes of hemodialysis. Samples were immediately precipitated with
ethanol, and after lipid extraction the dry residue was submitted to
HPLC and one minute fractions were bioassayed for rabbit platelet
aggregation. A leukocyte count was simultaneously performed using an
automated cell counter. PAF-acether was detected in the blood of 3
patients undergoing hemodialysis with cuprophan membranes with a
maximal production at 15 minutes (2.8 1.6 ng/ml). In these patients a
marked decrease in leukocyte number (60.3 18.4%) at 15 minutes was
observed, No PAF-acether production was detected in all patients
before dialysis and when polyacrylonitrile membranes were used. Thus
PAF-acether is produced and circulates in the vasculature during
hemodialysis with cuprophan but not with polyacrylonitrile mem-
branes. The present data indicate that PAF-acether must be considered
as a parameter in biocompatibility of hemodialysis membranes.
Short and long term study of renal blood flow and glomerular filtration
rate in patients with essential hypertension treated with captopril. A.
Martinez—Amenós, X. Pinto, J. Plana, J. Carratalá, M. Romero, X.
Gras—Balaguer, M. SantalO, J. Alsina, Hypertension Unit, Nephrology
Department, Hospital de Bellvitge, L'Hospitalet de Llobregat,
Barcelona, Spain. The renal plasma flow (RPF) (Hipuran 131) was
studied in 17 patients (p), mean age (ma) 47 10 years, 7 males. The
glomerular filtration rate (GFR) (lothalamate) was also studied in 9 of
them; 3 males, ma 47 9 years. All patients suffered from essential
hypertension and were treated with captopril (cap). A = pre-treatment
stage, B = short term: 1.5 1.2 months (m). Blood pressure (BP) went
back to normal levels during this stage with an average dose of cap =
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209 116 mg/day. C = long term: 55 12 mlater. Average dose of cap
= 100 43 mg/day. BP and blood creatinine were also measured.
A B C
FPR 601 176 564 155 505 98 mI/mm
FGR 114 34 121 30 127 95 1.73m2 mi/mm
TA sist. 181 18 145 13 153 15 mm Hg
TA diast. 111 14 91 5 96 10 mm Hg
Cr 81 25 78 36 99 42 mg%
The decrease in RPF was significant: A vs. B, P < 0.05; A vs. C, P <
0.01. The increase in GFR was not statistically significant. The decrease
in BP was statistically significant. A vs. B, P <0.01; A vs. C, P <0.01.
Creatinine did not change significantly in either B or C. Values found
are within normal levels. Conclusions: (1.) A significant reduction in
RPF is seen in both short and long term studies. (2.) The GFR does not
evidence statistically significant changes. (3.) The variations found in
renal hemodynamics are not accompanied by a decrease of renal
function as measured by creatinine levels.
Serum levels of thromboxane A2 (TxA2) in renal transplant (RT)
recipients. P. Gomez—Ullate, M.J. Dominguez, J.C. Fombellida, J.
Gainza, J. Montenegro, I. Lampreabe, Nuclear Medicine and Nephrol-
ogy, Cruces' Hospital, Bilbao, Spain. We studied the TxA2 behaviour
during the first twelve days after the renal graft to know the relation
between TxA2 and acute rejection (AR) index or acute tubular necrosis
(ATN), and to value the TxA2 in patients with functioning graft (PCr <
1.6 mg/dl) and in those with chronic rejection (CR), two months after
the RT. TxA2 was determined by RIA in: (1.) 16 patients with RT
functioning, (2.) 4 patients with CR, (3.) 6 (2 ATN, 1 AR, 4 RT
functioning) after RT. Results. An increase in the TxA2 levels was
observed between 3rd and 6th day (20 vs. 98 ng/rnl) in patients with
functioning RT. This increase appears between 9th and 10th day in
patients with ATN. In the case with AR, the peak (120 nglml) was in 4th
day postgraft, and two days before the clinical rejection crisis, In the
long—term study patients with normal RT had lower levels than those
with CR diagnosed in kidney biopsy (12.0 vs. 25.6). Conclusions. An
earlier increase of TxA2 appears in RT with normal renal function than
in those with ATN. The patients with TR functioning show lower levels
two months later the graft than the patients with CR in the long—term
study.
Lymphocytic infiltration of renal interstitial tissue in the acute cellular
rejection (ACR). L Hortal, J. Blanco, C. del Pozo, F. Coronel, E.
Gallego, I. Ubeda, A. Barrientos, S. Nefrologla, S. Anat. Patolog, H.
ClInico, Madrid, Spain. An increment of the mononuclear infiltration is
clearly established in the renal interstitial tissue in ACR. The appear-
ance of new monoclonal antibody techniques (MA) make it possible to
separate these cells in lymphocytic subpopulations (LS). We studied 18
episodes of ACR in 15 patients by transcutaneous renal biopsies. After
incubation with MA and immunoperoxidase, we differentiated the
helper subpopulation (OKT4) and the sitotoxic lymphocyte subpopula-
tion from the suppressor one (OKT8). We divided the sample in 4
groups (G): GI, 9 irreversible rejections; GIl, 9 reversible rejections;
GA, 7 patients under classic immunosuppression (AZA-Pred); GB, 11
patients under therapy with AZA-Pred-CsA. The rate OKT4/OKT8 was
<I in every sample, =0.4 0.24. Comparing the groups we got the
following results: The % of OKT8 in GI was = 27.7 6.2, and Gil,
= 24.8 8.4; P = NS. The % of OKT4 in GI was = 10.9 7.5, andGil, = 9.3 7.2;P = NS. OKT4/OKT8 in GI was = 0.4 0.2andGil, = 0.4 0.2; P = NS. The % Of OKT8 in GA was = 20.5 5.8
and GB, 5 = 30 6.7; P <0.01. The % of OKT4 in GA was = 6.2
2.7 and GB, 5c = 13.2 7.8; P <0.05. OKT4/OKT8 in GA was =0.31
0.16 and GB, = 0.46 0.26; P = NS. Conclusions. (I.) In ACR we
found the OKT4/OKT8 ratio <1 in all the episodes studied (N = 18).(2.) There was no significant difference in the infiltration of OKT4,
OKT8, OKT4/OKT8 and the rejection evolution. (3.) The patients who
received CsA showed an increase in both OKT4 and OKT8 compared
with those on classic therapy without change in the proportional rate
OKT4/OKT8.
The possible alternative on CAPD: Three exchanges/day. F. Coronel,
L. Hortal, P. Naranjo, C. del Pozo, J.C. Diez, J. Naranjo, A.
Barrientos, Servicio de Nefrologla, Hospital ClInico, Madrid, Spain.
The continuous ambulatory peritoneal dialysis (CAPD) as a stable
treatment of end—stage renal failure could be tiresome for the patient
that has to perform many bag exchanges daily. The alternative would be
to reduce the number of exchanges without lessening the dialysis
efficiency. We have studied 15 patients on CAPD (8 of them diabetics)
in two consecutive periods: 1st period, standard 4 exchanges of 2
liter/day and a follow—up of 152 months (m), ( = 10.3 5.5 m); 2nd
period, 3 exchanges of 2 liter/day and follow—up of 182 m ( = 12.1
5.3 m). Laboratory data and clinical situation was evaluated monthly
and EMG, ECG-ECO every 6 rn The adequacy of dialysis was done
with the relationship between BUN, urea generation rate (UGR),
residual creatinine clearance (RCcr) and peritoneal Ccr (PCcr). We
didn't find any clinical changes going from 4 to 3 exchanges. The
weight, UF, diuresis or arterial pressure didn't show significant differ-
ences, neither did the BUN, K, CO3H, P, Hb, Htc and tngl. The
creatinine, albumin and serum calcium increased with 3 exchanges (P <
0.05) with lower protein losses and PCcr (P < 0.05). In the diabetic
patients, it was possible to achieve a reduction in blood glucose, HbAlc,
trigl. and intraperitoneal insulin with 3 exchanges, but to no statistical
significance. The peritoneal infection incidence was reduced from I
ep/lO.8 pat-rn to 1 ep/14 pat-m. There weren't changes in EMG and
ECG-ECO. Using the parameters for the adequacy of dialysis only two
patients were in the 3 to 4 exchange limits. Results. A significant
number of patients on CAPD can benefit of the 3 exchanges-2/liter
schedule without losing dialysis efficiency, avoiding the drop out for
weariness. The relation between RCcr, PCcr, UGR can select these
patients.
Acute bypocalcemia in diabetic patients: Response of the axis PTH-
bone, I. Ubeda, L. Hortal, M.F. Martinez, F. Coronel, G. Balaguer, C.
del Pozo, A. Cruceyra, A. Barrientos, S. Nefrolog, H. ClInico, S. Bioq,
La Paz, Madrid, Spain. Diabetic dialysis patients infrequently develop
secondary hyperparathyroidism. That may be due to a defect in the
parathyroid gland and/or a certain bone resistance to PTH ac''n. In 6
diabetic and 6 non-diabetic dialysis patients (D and ND group) we
studied the Ca-P metabolism and the release of intact PTH (PTH-i) after
a fall of about I mEq/liter in the total serum calcium (TCa) through a
Ca-free dialysate HD. We determined the serum calcium recovery
during the following 23 hours. Both groups were similar in age, sex,
duration of dialysis, basal levels of PTH-i and absence of treatment with
any vitamin D metabolite or Ca supplements. Baseline data were similar
for TCa (mEq/liter) (D = 4.59 0.24; ND = 4.64 0.23), total proteins
(g/dl)(D = 7.08 ND 7.35 =4.06 l.1;ND
= 5.3 1.8), Ale. phosphatase (IU/ml) (D = 115.5 60.2; ND = 88
26.2), PTH-i (pmol/liter) (D = 17 11; ND = 12.9 5.2), 25-OH-D
levels are lower in group D: 8.16 2.6 vs. 17 3.6; P < 0.01. After a
fall of TCa of 1.028 0.15 mEq/liter (D) and 0.93 0.21 (ND) PTH-i
increased similarly in both groups: D = 33.2 12, ND = 21.6 7.8; P
= NS. After hypocalcemia, recuperation of serum calcium was slower
in the D group. Conclusions. (1.) Considering patients with a similar
parathyroid gland mass, the capacity of PTH release under an acute
hypocalcemia stimulation seems to be alike in both groups. (2.) P levels
were lower in D group and a worse recuperation of calcemia in the time
could explain the infrequent presence of osteitis fibrosa in diabetic
dialysis patients, through a bone resistance to PTH action.
Uremia: A hypercoagulable state? C. Quereda, A. Pardo, R. Marcén,
L. Orofino, S. Lamas, fL. Teruel, J. Ortuño, Hospital Ramon and
Cajal, Madrid, Spain. We analyzed coagulation abnormalities which
could predispose to thrombosis in 100 patients with chronic renal
failure: 56 on a hemodialysis (HD) program (I), 44 on conservative
treatment (II) and 50 healthy controls (III). We studied platelets (P1),
prothrombin (PT), thrombin (TT), fibrinogen (F), plasminogen (P),
plasminogen activator (basal and after 15 minutes of venous occlusion,
bPa, pPA), antithrombin III (AT III), factor VII, factor VIII coagulant
(Yule), antigenic (VII: Ag) and von Willebrand (VIII: vW and lupus
like anticoagulant (LA). The following results differ significantly from
the control group:
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Group F bPA pPA ATLII VilIc LA (%)
x 356 80 190 91 199
ISD 99 53 116 11 83 30
x 411 92 246 103 233
IISD 118 44 75 16 89 11
x 288 112 318 99 105
III SD 47 11 69 12 28 0
Sixteen percent of the patients presented some thrombotic event. In
group I patients with thrombosis had been on HD for a longer period
and had a higher number of fistula (2.6 1.5 vs. 1.5 1.2, P <0.05).
We conclude that in uremia, and specially in HD, there are alterations
in fibrinolysis and in vascular wall regulating factors which increase the
risk of thrombosis. The high incidence of LA is a fact which has not
been described previously.
Non-A, non-B hepatitis in hemodialysis patients: Evolution after renal
transplantation. R. Matesanz, L. Orte, F. Liaño, J.L. Teruel, J. Ortuno,
Hospital Ramón and Cajal, Madrid, Spain. We studied the evolution of
35 patients diagnosed with NANB hepatitis while on HD treatment
(enzymatic elevation in the absence of cardiac failure, hepatotoxic
drugs and seroconversion for CMV, EBV, virus A and virus B) after
receiving a functioning kidney graft on conventional immunosuppres-
shin (azathioprine, and prednisone) with a follow—up of 12 to 54 months.
According to the clinical evolution on HD they were classified as:
acute, 13 (37%); and chronic (>6 months), 22 (62%); 9 of them with
undulating pattern. Alter transplantation serum albamin—transferases
became normal in 5 and remained elevated in 17 of the 22 chronic
patients (48% of the 35 NANB patients), but with a non-aggressive
clinical and histological evolution (no development of cirrhosis or
hepatic failure and few signs of activity in 6 patients with hepatic
biopsy). Enzymatic elevation at the time of transplantation (8 cases) did
not carry a worse prognosis. There were no reactivations in the 13
patients with acute hepatitis on HD. However, 3 of them developed a
veno-occlusive disease (VOD) with hepatic failure and death in two;
only I of 84 patients of our transplant recipient population with similar
follow—up period developed VOD. About 50% of transplanted patients
with NANB hepatitis on HD showed chronic evolution, but its clinical
and histological outcome seems to be rather benign and is not worsened
by renal transplantation. The relationship between NANB hepatitis and
VOD, if any, remains uncertain.
Symptomatic hypotension (SH): Relative intolerance of membranes and
hemodialysis (HD) fluid. C. Quereda, L. Orofino, J, Sabater, R.
Marcén, S. Lamas, J. Ortuño, Hospital Ramon and Cajal, Madrid,
Spain. SH is the main cause of morbidity in HD. To evaluate the
contribution of different factors to its incidence we analyzed 384
sessions in 8 patients (7 female, I male) with a high index of SH (30 to
90%). Eight periods resulted from combining 3 variables: dialyzer (D);
cuprophan (CU); polyacrylonitrile (PAN); dialysate temperature (DT),
35° or 37°C; and dialysate sodium (DNa), 133 or 139 mEq/liter, Patients
were randomly included in one or other period, remaining stable along
the study. The % of sessions with SH (systolic blood pressure 90 mm
Hg) is shown below. Number of sessions per period was 48.
HD D+DT+DNa %SH HD D+DT+DNa %SH
1. CU+37+133 64 2. PAN+37-i-l33 52
3. CU+35+133 42 4. PAN+35+133 37
5. CU+37+139 37 6. PAN+37-i-139 33
7. CU+35+139 27 8. PAN+35+139 15
Incidence of SH was lower with 35°C in the study as a whole (30 vs.
47%, P < 0.001) and with both membranes: CU (34 vs. 51%, P < 0.01)
or PAN (26 vs. 43%, P < 0.01). It was also lower with DNa 139 in all
sessions (28 vs. 49%, P < 0.001) and considering either CU (32 vs. 53, P
<0.01) or PAN (29 vs. 45%, P < 0.01). SN appeared less frequently with
PAN, though differences between membranes were not significant (34 vs.
40%, NS). Modification of dialysate (DT, DNa) allows important improve-
ment of SH with independence of membrane material. The combined use
of low DT and high DNa potentiates the effect of each one alone.
Study of ischemic heart disease in hemodialysis (HD) patients with
thallium-201 dipyridamole scintigraphy. S. Lamas, L. Orofino, C.
Quereda, R. Marcén, F. Barcia, f.M. Castro, P. Alonso de Caso, J.
Ortuño, Nephrology, Cardiology and Nuclear Medicine Departments,
Hospital RamOn and Cajal, Madrid, Spain. Cardiovascular disorders,
especially ischemic heart disease, are the main cause of morbidity in
HD patients. In order to assess the relationship between angina pectoris
and underlying myocardial ischemia using non-invasive methods we
studied 25 patients divided in 3 groups: (A) 10 patients with angina in or
out of dialysis (8 male and 2 female, age, 60.3 8.8); (B) 7 patients
without angina who were similar in age, sex, time on HD and hemato-
crit; (C) 8 young patients without angina (age 33.1 9.7). By the use of
EKG, x-ray and echography we studied the presence of associated
cardiac disease. EKG showed ischemia only in I patient of group A.
Left ventricular hypertrophy was the most frequent finding in patients
of groups A and B (70 and 100%). Calcification of aortic arch was
present in 80% patients of group A, 28% of group B and 12% of group
C. In conclusion: (1.) Thallium201-dipyridamole scintigraphy reveals
subclinical ischemic heart disease in a significant number of cases. (2.)
Isehemic heart disease is probably underestimated in HD patients.
Incidence of HIV antibodies in patients on hemodialysis (lID) and renal
transplants (RT). E. Gomez, A. Martinez, F. Fdez—Vega, S. Aguado, R.
Mann, J. Alvarez Grande, Nephrology and Microbiology Services,
Hospital Covadonga, Oviedo, Spain. HD and RT are immunodepressed
and frequently receive blood transfusions, that's why they could have
an increased risk of having AIDS virus infection. Anti-HIV antibodies
had been studied in HD and TR patients in the Public Hospital in our
community. ELISA was the screening method employed (ABBOTT
until December 1985 and PASTEUR since January 1986). Sera with
persistent positive results were sent to a Reference Laboratory
(Majadahonda, Madrid), where ELISA test was done again, and
indirect immunofluorescence test was also performed to confirm the
positive results. A total of 181 patients were studied: 145 HD (89 males
and 56 females), between 22—71 years old ( SEM: 50.6 1.1), who
had been on hemodialysis for 3—114 months (37 2.4) and who had
received none to 61 blood transfusions (8.1 0.8). There were 36
patients (23 males and 13 females) with functioning RT, aged 18—58
(38.9 2), having been previously on hemodialysis for 6—109 months
(30.4 4.4), blood transfusions 1—43 (10.5 1.2). All of them denied
other risk factors for AIDS virus infection. Ten patients out of 181
(5.5%) had specific anti-HIV antibodies (ABBOTT ELISA test in all
cases), 5 were on HD and 5 had RT. On retesting by another ELISA
(PASTEUR) and IF, all of them were negative by both methods. A
higher frequency of false positive results in TR was noticed in those
who had more blood transfusions, but this was without statistical
significance. Age, sex, time on HD and hepatitis B virus immunization
were also without statistical significance. Conclusions. (I.) The actual
incidence of specific anti-HIV antibodies in our patients (HD and TR)
was none; that's why its seems unnecessary to perform a routine deter-
mination in this group of patients. (2.) Some commercial ELISA tests give
false positive results, so the results mut be interpreted with caution.
Absence of factor H and membranoproliferative glomerulonephritis
(MPGN). E. Gomez, C. Lopez Larrea, A. Dieguez, F. Fdez Vega, S.
Aguado, J. Alvarez Grande. Nephrology Service, Immunology L,
Hospital Covadonga, Oviedo, Spain. The deficit of certain proteins in
the classical pathway of the complement is associated with various
types of glomerulonephritis and infections. Protein deficiencies of the
alternative pathway are unusual. We have had the opportunity to study
a nine member family composed of the parents and seven children, in
which three daughters aged 12, 16 and 26 presented a pattern of
nephrotic syndrome and progressive renal failure. Their evolution was
as follows: one died from a sepsis, another requires hemodialysis, and
the last one presents a moderate renal failure. In two of them a biopsy
was carried out, and it showed a MPGN type I; they had sepsis caused
by Neisseria miningitidis at the age of 11 and 13, respectively. The
immunological study included the determination of: CH5O (hemolytic
method), Clq, C3, C4, CS, C9, Cl INH, factor B, factor I and factor H
(radial immunodiffusion, nephelometry andior Laurell Rocket), C3 Nef,
immunoglobulines, cryoglobulines, ANA, antiDNAn and HBV markers
(habitual techniques). From 2 to 5 samples were studied in a period of
three years. Alterations were only found in affected siblings: CH5O <
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5UH; C3, C5, factors B and H undetectables; C9 diminished. The C3
Nef was negative and the rest of parameters were normal. The absence
of factor H was confirmed by SDS-PAGE techniques. This family
constitutes an exceptional case of absence of factor H. The lack of
factor H produces inability to control the C3b dependent feedback
system of the alternative pathway, which is followed by continuous
hypercatabolism of C3 and subsequent expense of the other proteins
(factor B, CS, C9), which explains the pathological and the changed
complement profiles of the patients.
Evolution of lipid metabolism in renal transplantation. J. Cabezuelo,
L. Pallardo, M. Gimenez, M. Breto, J.M. Cruz, Servicio de Nefrologia,
Hospital General La Fe, Valencia, Spain. In 114 renal transplant
patients we have checked serum triglycerides, whole cholesterol, HDL
cholesterol, and (LDL+VLDL) cholesterol every three months the first
year and yearly afterwards. In addition, in 38 patients we checked the
apolipoprotein A and apolipoprotein B. Results. After renal transplan-
tation, comparing to the levels in hemodialysis, there were an early
decrease of triglycerides (P < 0,01), and a persistent increase of
cholesterol (P < 0.01), as well as its fractions HDL cholesterol and(LDL+VLDL) cholesterol; so the ratio (LDL+VLDL)/HDL choles-
terol did not change (P, NS; Fisher test). The apolipoprotein A showed
an increase during the first year post-transplant, with a later reduction
to similar levels to those in hemodialysis when the maintenance
prednisone dose was reached. The apolipoprotein B increased in the
first year, and a significant correlation was found with the relative
weight gain (P < 0.01). In the same way, whole cholesterol, HDL
cholesterol, and (LDL+VLDL) cholesterol showed a significant corre-
lation with the relative weight gain also (P < 0.05). However, there was
not a significant correlation of the prednisone dose and the serum
creatinine with triglycerides, whole cholesterol, HDL cholesterol,
(LDL+VLDL) cholesterol and apolipoprotein A. In conclusion, renal
transplantation modifies the plasma lipids, but into a range that must not
increase significantly the aterogenic risk.
Low dose of cyclosporin and azathioprine in renal transplantation. L.
Pallardo, J. Garcia, J. Sanchez, J. Cabezuelo, R. Moreno, P. Antonio
y J.M. Cruz. Servicio de Nefrologia, Hospital General La Fe, Valencia,
Spain. In order to reduce cyclosporin toxicity, 45 renal transplant
patients (1 living donor, 6 second transplants), received low dose of
cyclosporin (7 mg/kg), azathioprine (1.5 mg/kg, stopping after two
months), and prednisone (30 mg). Results. Twenty—one patients (46%)
had ATN that lasted 12.5 5.0 days. Sixteen patients (35%) had acute
rejection episodes 10.3 3.0 days post-transplant, all corticosensitive(3 boluses of 500 mg methyiprednisolone). The hospital stay of the
group at discharge was 14.6 5.9 days. After a mean follow—up of 5
months (2—9 months) there have not been any immunological graft loss.
Forty—one grafts are at present functioning with a mean serum creati-
nine of 1.6 0.4 mg/dl; none has proteinuria higher than 0.5 g/day and
18 patients (40%) have high blood pressure, The prednisone dose at 3
and 6 months is 14.5 0.8 mg and 11.4 0.8 mg/day, and the
cyclosporin dose 373.1 67.3 mg and 293.8 93.9 mg/day, respec-
tively. Two grafts were lost because of arterial thrombosis, and a third
one due to urinary fistula. One diabetic patient died due to urinary
fistula and secondary sepsis, and only two patients had leukopenia.
Cyclosporin nephrotoxicity was a minor problem modifying the doses
attending to the plasma levels. In conclusion, low doses of cyclosporin,
associated to transient azathioprine administration in the postoperative
period, reduces the nephrotoxicity, simplifying its use, and they are as
effective as the doses given in conventional cyclosporin protocols.
Carpal tunnel syndrome (CTS) with amyloid deposits (AD) in chronic
hemodialysis patients (CHDP). V.M. Valverde C., A. Liopis L., Depart-
ment of Nephrology, Perpetuo Socorro, Alicante, Spain. CTS has been
observed with an increasing frequency in CHDP. Two presentation
patterns have been reported: one of them with early presentation is
reported frequently in diabetics, and the other one with a delayed
pattern, developed some years after hemodialysis (HD) initiation.
Describing 29 patients with diagnosed CTS among a population of 168
CHDP, myeloma, amyloidosis or with a recurring infection CHDP were
excluded, Total population mean age was 59.1 years (16 to 83) with HD
mean time of 68 months (9 to 146). CTS patients mean age was 52.3
years with HD mean time of 80.7 months (43 to 138). In 23 patients CTS
was bilateral. Kidney diseases such as frequently thrombosed A-V
fistula and degree of hyperparathyroidism were similar in both groups.
Patients undergoing HD more than five years have been preferentially
treated with cuprophane membranes. In 12 patients a symptomatic
improvement was obtained after local inifitration with Triamcinolone,
still under observation. In 17 patients a surgical release of median nerve
was made. In 8 patients it has been bilateral. In 14 patients AD were
identified with Congo Red stain, all of them sensitive to KMnO4. No
immunohistochemical techniques to define AD components (B2-micr-
oglobulin?) were done. We conclude that the permanent time in HD is
significantly associated with CTS, possibly " ... clinical expression of a
systemic disorder by deposits inducted by HD (acute fase reactants
activated by poor biocompatibility) or by a limited clearance of deter-
mined molecules (Bz-microglobulin?).
Kidney transplantation from cadaveric donors in patients with previous
positive and actual negative cross—match. F. Lozano, M. Plana, J.
Martorell, A. Gayá, 0. Viflas, 0. De la Calle, J.M. Griño, J, Andreu,
J. Lioveras, R. Solá, L. Capdevila, A. Vila, J. Vives, Servei d'Im-
munologia, Hospital Clinc i Provincial, Villarroel 170, Barcelona
08036, and Kidney Transplantation Units of Catalunya, Spain. The
cross—match has been considered as an essential test to decide a kidney
transplantation. Few years ago, some authors proposed to transplant
patients with a previous positive and actual negative cross—match, but
experience about their evolution is scarce. In order to present our
experience in this field we have retrospectively studied a group of 15
patients transplanted by the Kidney Transplantation Units of Catalunya
in the last 12 months, meeting the criteria mentioned below. This group
consisted of 8 males (53.4%) and 7 females (46.6%) aged from 10 to 59
years ( 35.4 15.1), representing the 5.17% of the whole cadaveric
transplantations in the same period of time. The mean of HLA A-B-DR
matches was 2.3 1.1. All patients received a minimum of three blood
transfusions and three of them (20%) had a previous unsuccessful
kidney graft. The 87% of total patients had lymphocytotoxic antibodies
at some time before the kidney transplantation, but only 33.4% of them
were still positives at the time of transplantation. The mean period of
time between the last positive and the actual negative cross—match was
12.7 11 months (from 3 to 47 months). The post-transplant follow—up
was from I to 12 months with a mean of 6 3.4 months. For the first
6 months of follow—up, both graft (87%) and patient (87%) survivals in
this group were similar to the observed in the whole transplanted group
(75% and 93%, respectively). In only 2 patients the graft failed and the
patients also died, but there are not differences between them and the
group of patients with functional graft. The 2 mentioned patients were
female and hypersensitive (>70% of lymphocytotoxic antibodies), and
they also had negative antibodies against panel at the time of transplan-
tation. In summary, these data encourage us to continue the practice of
kidney transplantations in patients with a previous positive and actul
negative cross—match. In addition, this fact would contribute to dimin-
ish the accumulated number of hypersensitized patients without suf-
fering an over—risk.
Stopping prednisone (P) in renal transplant (RT) recipients taking
cyclosporine (CsA): Safety conditions. J. Lloveras, X. Cuevas, A. Orfila,
M. Mir, J. Aubia, J. Masramon, Hospital G.M.D. L'Esperanca,
Barcelona, Spain. CsA is given 14 mg/kg/day for the the first week after
transplantation and reduced 2 mg/kg each subsequent week up to 8
mg/kg/day. Doses are thereafter adjusted to trough whole blood levels
and CsA nephrotoxicity. Patients receive in addition P 25 mg/day from
the day of RT which is progressively reduced to 15 mg/day by the end
of the sixth week. At the beginning of the fifth month P is steadly steps
reduced to total withdrawal by the end of the sixth month post-RT. This
schedule is applied to all CsA recipients that did not present episodes of
rejection (63.3%). Patients presenting a rejection episode during the first
6 months after transplantation have the same schedule restarted after
rejection treatment is completed. Patients that received antithymocyte
globulin and those that had the CsA discontinued for any reason were
excluded from the trial. Thirty—nine adult recipients (34 cadaver and 5
parent to son) had the P stopped either 6 months after RT (25 pat.) or 6
months after rejection (14 patients). The mean follow—up after P
withdrawal is 7.3 3.8 months (2—19 m). At the time of P discontinua-
tion the CsA dose average was 4.2 0.9 mg/kg/day (2.5—6 mg/kg/day);
CsA blood level average was 571 169 ng/nil (315—923 ng/ml); plasma
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creatinine average was 1.6 0.3 mg/dl (0.8—2.5 mg/dl). CsA blood
levels after P discontinuation were similar to respective previous values
in all patients. One of the patients presented a reversible rejection
episode 10 days after P discontinuation, their CsA blood levels being
around 550 ng/ml. None of the remaining patients presented a rejection
episode during the whole forementioned follow—up period. We think
that 400 ng/ml (RIA, whole blood) may be a tentative good low "safe"
level for a majority of patients off P, provided that plasma creatinine of
our patients are not higher than those published in most reports.
More than three years of cyclosporine (CsA) use in renal transplanta-
tion (RT). J. Lloveras, X. Cuevas, 0. Orfila, M. Mir, J, Aubia, J.
Masramon, Hospital G.M.D. L'Esperanca, Barcelona, Spain. From
April 1983 up to June 1986, 75 RT received CsA as the initial
immunosuppressor. CsA was given 14 mg/kg/day for the first week after
RT and reduced 2 mg/kg each subsequent week up to 8 mg/kg/day.
Doses are thereafter adjusted to trough whole blood levels and CsA
nephrotoxicity. Patients initially received low doses of prednisone
which in most cases was discontinued 6 months after RT. Sixty RI of
the 75 RI were from cadaveric donors and the remaining 15 RT from
haploidentical living donors. Eight RT were second RTs and 6 other RT
were on sensitized recipients (>60% of cytotoxic antibodies). Seven RT
were type I diabetics, aged 13 to 60 years (17 RT older than 50 yr).
Acute tubular necrosis (dialysis required) incidence in cadaveric RI
was 25% (15 RT). One year and 2 years actuarial patient survival was
95.4% and 93.1%, respectively, and 1 year and 2 years actuarial graft
survival: 86.4% and 84.0%. All living donor grafts, second RTs and
sensitized recipients have the kidney functioning. ATG treated RT
(corticoresistant rejection—biopsy proved), were 8 RT. Iwo RT
changed to azathioprine. Rejection incidence was 26 RT (35%). First
rejection interval from transplantatigon was : 46 days. Serum creati-
nine at 3,6, 12 and 24 months was 2 mg/dl, 1.8 mg/dl, 1.7 mg/dl and 1.6
mg/dl, respectively, CMV infections were 18 RT (24%). We analyzed
the cause of deaths and graft losses. We expanded CsA nephrotoxicity
management and we compared these results with our historic control
group immunosuppressed with azathioprine.
The autonomic nervous system in hemodialysis (HD). A. Bondia, J.M.
Tabernero, J.F. Maclas, C. Martin—Luengo, M. Urrutia, University
Clinical Hospital, Salmanca, Spain. Fifty—two patients with chronic
renal failure on hemodialysis were assayed for the existence of global
autonomic neuropathy (AN), using the valsalva index (VI). Ihe values
in the patients were 1.46 0.3, lower (P < 0.0005) than the controls
(1.69 0.33). No correlation was found between VI and orthostatic
hyptension, intradialysis hypotension, motor nerve conduction velocity
or parathormone. Having demonstrated the existence of AN, the
different segments of the autonomic reflex arc were studied to try to
locate the damage. We studied 8 healthy subjects and 10 patients on
intermittent hemodialysis by intraarterial monitoring of arterial pres-
sure (AP) and cardiac rhythm (CR). The following are tests with the
most significant results:
Tests Controls Patients P
Phenylephrine
common afferent fibers
Regression coefficient
0.62 0.24 0.03 0.09 <0.0005
Hyperventilation
vasomotor center
Decrease in AP
28.82 6.29 30.7 13.49 NS
Cold pressor
sympathetic afferent
fibers
Increase in AP
23.73 13.45 42.39 12.86 <0.005
Atropine
vagal afferent fibers
Increase in CR at 0.015 pg/kg
59.25 18.6 21.9 14.2 <0.001
Tyramine
extradrenal
noradrenaline
deposits
Dose to raise AR to 21 mm Hg
1,700 g 1.000 pg
Epinephrine
terminal organ
Pupil diameter
Unmodified Unmodified
A clear alteration is observed in baroreceptors which in turn leads to
adrenergic hyperexcitability reflected in the hypersensitivity of the
sympathetic efferent route and a greater response to the release of
extraadrenal adrenalin. The lower response to atropine is indicative of
vagal alteration.
Mitogenic effect of the peritoneal effluent (PE) on mice fibroblasts
cultures in CAPD patients (PTS). R. Selgas, A. Lopez—Rivas, M.V.
Cuesta, J. Muñoz, E. Huarte, A. Sanz, Hospital Ia Paz and Centro de
Biologia Molecular, UniversidadAutonoma de Madrid, Spain. Individ-
ual susceptibility for developing peritoneal functional modifications in
CAPD has been demonstrated. Transient or permanent mesothelial
denudation or hypermeabiity could induce direct contact between PE
and peritoneal fibroblasts. This fact could condition an activation of
these cells and consequently a peritoneal fibrosis and so a functional
derangement. The PE mitogenic activity and its possible relationship
with bioactivity—related parameters were studied in 18 pts in CAPD.
Both PE and blood samples were studied for: immunoglobulins, a-I
antitripsin, fibronectin, A fibrinopeptide, fibrinogen, FDP, plasmino-
gen, fibrinolytic activity in plates, C3 and C4. Peritoneal diffusion
capacity for small molecules was determined through mass transfer
coefficient determination (MTC). PE was studied for cellular cultures
activity in a mice fibroblast Swiss 313 don-quiescent type in a culture
plate following its contact with 10% fetal bovis serum + PE. A
maximum stimulus control with insulin + forbol esther was used. The
parameter used to measure stimulation was H3 timidin incorporation
(counts per minute = cpm). Results. PE mitogenic activity didn't show
any relationship with time of treatment or number or aggressivity of
previous peritonitis. The values ranged between 7288 cpm (no stimulus)
and 70873 cpm (maximum) with a mean value of 40000 cpm. MTCs did
not correlate with mitogenicity of the PE. PE fibrinopeptide level in pts
with no beta blocker intake correlated with mitogenic capacity (r: 0.59,
P < 0.05, N: 12). Pts with previous beta blocker intake showed a
relationship between mitogenicity and a-l antitripsin PE levels (0.58, P
<0.05). In conclusion, the PE mitogenic capacity in CAPD pts is quite
different among these pts; some of them could be in high risk of suffer
peritoneal fibroblasts activation which could degenerate to peritoneal
sclerosis. The mitogenic activity origin has not been determined in this
study.
Diabetics treatment with CAPD: Results with three different systems.
R. Selgas, J. Muñoz, E. Huarte, J.L. Miguel, C. Riflon, A. Sanz, L.
Sanchez—Sicilia, Hospital La Paz, Madrid, Spain. Nineteen diabetic
patients (pts) have been treated with CAPD using three different
systems in the last 3 years (216 patient—months, mean 11 months).
Systems were: 1-1 with a spike connector (3 pts), F-l with a luer-lock
connector (8 pts) and T-UV with a ultraviolet germicide chamber (8
pts). Epidemiological data were similar in these groups; blindness was
present in 47%. Insulin was administered through peritoneal route in the
first 10 pts during their first period on CAPD and subcutaneous in the
subsequent period and in the rest of the pts. Inclusion in each group was
only chronologically decided. Partner support was needed in 100, 50
and 37% of the pts, respectively, which increased to 100, 100 and 50%
in the blind people. Results. Actuarial survival at 6 months and 1 year
were 100/100, 100/83 and 100/-%, respectively. Technique success rates
were: 100/100, 100/57 and 80/-%. Adaptation (pt criteriaimedical crite-
ria) was good in 100/67, 75/62 and 86/71%, respectively, Intraperitoneal
vs. subcutaneous insulin: better metabolic control with i.p. route was
achieved but hypoglycemias and peritonitis were more frequent (10
episodes or 1/13.5 pt-month vs. 2 episodes or 1/40.5 pt-months). The
overall peritonitis incidence in each group was: 1/31, 1/13 and 1/40.5
pt-months, respectively. Germens: 6 gram +, 1 gram —, 2 negative
cultures, 2 non-valid and 1 non-available. In 7 cases, malpractice was
recognized by pts. The episode in UV system was caused by Strept.
Mitis. The use of partner carried out an overload for him. In conclusion
we feel that CAPD is useful for diabetics with good results. Handle
systems needed more relatives' support with consequent worse results.
UV is useful for blind patients with no aid. Intraperitoneal insulin
increases the incidence of peritonitis with no better metabolic control.
The devices used reduces patient malpractice possibilities.
Betabalockers (BB) Induce functional changes which potentially injure
peritoneum in CAPD patients (PTS). R. Selgas, E. Huarte, F. Escuin, J.
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Mufloz, A. Sanz, M.E. Martinez, L. Sanchez—Sicilia, Hospital La Paz,
Madrid, Spain. Beta blockers (BB) are widely used drugs among ESRD
patients (pts). Scierosing peritonitis (SP) is a major concern for CAPD
pts. SP has been related with Practolol (a BB) intake. Probably SP is the
result of fibroblasts activation after mesothelial denuded pentoneum.
Our objective was to study if BB could induce peritoneal functional
changes. For this purpose we have studied the peritoneat diffusive
capacity (mass transfer coefficients = MTC) in 26 CAPD pts sequen-
tially during 3 years. Pts were grouped according to BB intake and
peritonitis (P) incidence: 10 pts no BB + 1-2 P; 7 pts BB + 1-2 P; 5 pts
no BB + no P; and 4 pts BB + no P. These groups were similar in
epidemiological data; diabetics or pts with severe P were not included.
Results. The total population showed no significant changes in MTCs
values after this period. However individual groups did: pts who took
BB had a higher creatinine-MTC after three years in CAPD (11.2 3.8
vs. 8.4 3 mi/mm, P < 0.05); no differences between their respective
urea-MTC were found. Sequential analysis of MTC values (paired data)
reflected no significant changes for urea-MTC, independent on BB
and/or P; a significant increment of creatinine-MTC in the BB group,
further if they have passed P. was found (9.1 3.4 to 12 4 mI/mm, P
<0.05). We conclude that BB induce a peritoneal permeability incre-
ment for creatinine in CAPD pts. If this increment represents an overall
permeability increasing, that is a loss of certain mesothelial properties,
BB could favor chronic peritoneal injury.
Function of peritoneal (FP) in diabetic (D) patients (PTS) on CAPD. R.
Selgas, R. Madero, J. Munoz, E. Huarte, M.P. Fontán, J.L. Miguel, L.
Sanchez Sicilia. Hospital La Paz, Madrid, Spain. Certain individual
peritoneal characteristics influencing on FP have been described in
CAPD pts. D pts could show capillary wall abnormalities, which affect
its permeability. We have studied 15 D-pts and 31 non-D, with CAPD
recently initiated. FP was studied through mathematical modelling
techniques to determine peritoneal mass transfer coefficient (MTC) and
ultrafiltration (UF). Previous metabolic control was appropriate. We
evaluated: hypertension, retinopathy, Hcto, Albumine, PTH, calcium
and nerve conduction parameters. Multivariant, factorial and linear
regression analysis were performed. Results. MTC values were for urea
22 5.6 (D) vs. 20 5.3 (non-D), creatinine 8.7 4.3 (D) vs. 9.9 4.2
(non-D) and UF 1.5 0.4 (D) vs. 1.3 0.4 (non-D) ml/min.
Multivariant analysis of these 3 variables showed significant differences
between D and non-D (P < 0.004). Linear regression analysis showed
the following significant relationship for D: urea-MTC-IJF (—0.54) and
body surface (bs) (—0.46), creatinine MTC-bs (—0.55). Quotient MTCs-
albumin (0.75) and height (0.51), UF-Hcto. (—0.64). The other param-
eters did not show any relationship with FP. Factorial analysis grouped
FP defining parameters. Our data might reveal the existence of a
diabetic peritoneopathy, characterized by an increased blood flow per
pentoneal functioning area unity and a decrease in the capillary wall
permeability.
Coagulation and hypercoagulation inhibitors in the nephrotic syn-
drome. Analysis of heparin co-factor II, antithrombin III and C protein.
A. Oliver, P. BarcelO, J. Felez, J. Fontcuberta, J.A. Ballarin, F.
Calero, G. del Rio, Fundacion Puigvert, Barcelona, Spain. The
hypercoagulability of the nephrotic syndrome (NS) can be provoked by
urinary loss of coagulation inhibitors. Plasma and urinary levels of
antithrombin III, heparin co-factor II and C protein were measured in
29 patients: 18 males and 11 females aged 34—6 years during the
nephrotic phase (proteinuna > 3.5 g/24 hr) and remission phase(proteinuria < 1 g/24 hr). In each case prekalikrein, Cl inhibitor,
plasminogen, a2-antiplasmin and albumin clearance, IgG, transferrin
and a2 macroglobulin values were determined. Plasma values of C
protein, co-factor II and antithrombin III were 112 17; 87 14 and 90
16 in the nephrotic phase and 87 15; 74 19 and 100 12 in
remission phase (normal in both phases). Urinary loss of C protein and
antithrombin III were higher in the nephrotic phase, 110 15 and 64
20, than in remission, 33 9 and 17 8, and there was a direct
correlation with the degree of proteinuria (P < 0.01). Albumin, C
protein and antithrombin clearances were: 182.5 34, 9.6 4.7 and 252
51.4 d/min in the nephrotic phase and 83 21, 3,2 1.1 and 27
9 t1Jmin in remission. The selectivity of the proteinuria did not
influence the clearance of C protein and antithrombin III even in their
urinary elimination. These data indicate that the urinary loss of coagu-
lation inhibitors does not participate in the hypercoagulability of the
nephrotic syndrome. The different behavior of the clearances suggests
that cationic charges intervene in the filtering of proteins by the basal
glomerular membrane.
Acute renal failure after topical application of diethylene glycol (DEG).
MC. Cantarell, J. Fort, J. Camps, J. Madrenas, M. Sans, M.
Rodamilans, L. Piera, Service of Nephrology and Pathology, Hospital
General "VaIl d'Hebrón, Service of Toxicology, Hospital Clinico,
Barcelona, Spain. The Burn Unit of our hospital has a 1.6% incidence
of acute renal failure, and the sole etiology observed is the
rabdomyolisis that follows electrical burns. During a three month
period, we observed five patients with second and third degree burns
involving 7 to 62% of the body surface, that developed acute renal
failure. All received the same type of fluid and electrolyte replacement
and were treated topically with silver sulfadiazyne. Between the third
and fifth day of treatment, they developed oligoanuric renal failure with
metabolic acidosis and increased anion gap together with neurologic
abnormalities and in the last patient, liver dysfunction. In each case
there was a rapid deterioration that was soon followed by death. A
pharmacologist examination of the silver sulfadiazyne revealed that the
excipient contained DEG-stearate and free DEG. Post-mortem finding
showed toxic liver changes and in the kidneys there was an acute
tubular necrosis with ballooning and loss of intracellular material in the
tubular cells. These findings were considered suggestive of DEG
intoxication. As soon as we established the diagnosis in the last case,
the preparation was withdrawn from the market. No new intoxications
have occurred since the last episode registered eighteen months ago.
Effect of renal transplantation on the calcium phosphate vitamin D and
parathyroid derangements in the uremic patient. A.M. de Francisco,
J.G. Cotorruelo, J.A. Amado, J. Riancho, C. del Arco, J.A.
Zubimendi, M. Arias, Hospital Nacional "Valdecilla", Santander,
Spain. We studied 81 patients with functioning renal grafts. Blood and
urine were collected for measurement of: total calcium, phosphate,
alkaline phosphatase, magnesium, albumin, creatinine, parathyroid
hormone (COOH and Ntact), bone GLA protein, calcitonin, alumin-
ium, 1 .25(OH)2 vitamin D, urinary calcium and phosphate, TmP/GFR
and hydroxiproline. (1.) Hypercalcemia was present in 17% of the
patients and in the majority the onset was within six months. Secondary
hyperparathyroidism (in eleven out of 12 hypercalcemic patients) was
the main cause of post-transplant hypercalcemia. (2.) Hyperparathy-
roidism and relative deficiency of 1 .25(OH)2 vitamin D were causative
factors in the occurrence of hypophosphatemia (16%). In some patients
with low TmP/GFR and normal PTH values a primary renal phosphate
leak is postulated. (3.) Secondary hyperparathyroidism was present in
38% with normal renal function and in 77% with moderate renal failure
(Crs 1.5—3 mg%). Evidence of the peripheral action of parathyroid
hormone with significatives differences in BGP TmP/GFR and
1.25(OH)D3 was observed in the high PTH group. (4.) Although
1 .25(OH)2 vitamin D returns to normal values after successful grafting,
a relative deficiency of 1.25 synthesis is present in some patients with
normal renal function and low—normal I .25(OH)2 vitamin D levels in
spite of hyperparathyroidism and/or hypophosphatemia. (5.) Eight
patients (10%) developed aseptic hip necrosis. Hypercalcemia occurred
in three and secondary hyperparathyroidism in all the affected patients.
The effect of cyclosporine (CsA) on native renal function in non-uremic
diabetic patients with pancreas transplantation (PX). AM. de Francisco;
D. Casanova; D.E.R. Sutherland; F.C. Goetz, S.M. Mauer, J.S.
Najarian, Dept. of Surgery University of Minnesota, USA, Hospital
Nacional "M. Valdecilla", Santander, Spain. Thirty—three type I
diabetic patients, 10 male and 23 female, age 16 to 46 years (mean SD
30 7) were evaluated before and after pancreas transplantation, 18
from cadaver donors and 15 from related donors. Duration of diabetes
at the time of PX ranged from 14 to 41 years (mean SD 21 7). The
patients had not received kidney transplants and were not uremic,
serum creatinine ranged from 0.4 to 1.6 mg/dl (mean SD 1.0 0.3
mg/dl). Cyclospormne was administered at a maintenance dose of 6—8
mg/kg/day after 10—14 mg/kg/day (13 patients) or 3 mg/kg/day i.v. (20
pts). The dose was adjusted to achieve whole blood levels around 200
ng/ml. Prednisone, azathioprine and antilymphocite globulin were also
given according to different protocols. The mean (±sD) serum creati-
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nine (mg/dl) and creatinine clearance (mi/mm) were: 1.0 0.3 and 90
34 (before pancreas transplantation) 1.5 0.6; 55 23 (two weeks); 1.4
0.4; 62 22(6 months); 1.4 0.5; 58 13 (1—2 years); 1.5 0.2; 63
16 (2 years). Three out of 13 recipients with functioning grafts for
more than one year had an urinary albumin excretion in excess of 400
mg/24 hr. Twenty—six, 16, and 14 months after successful pancreas
transplant there was an important reduction in urinary albumin excre-
tion. The mean decrease over the pre-transplant values was 95 4 per
cent. We conclude that long—term administration of cyclosporine in
non-uremic patients after pancreas transplantation produces a decline
in GFR soon after CsA therapy and remains stable thereafter. A
reduction in urinary albumin excretion has been observed after suc-
cessful pancreas transplantation on cyclosporine therapy,
Effect of parathyroidectomy (PTX) in bone aluminium accumulation in
uremic patients. A.M. de Francisco, H.A, Ellis, M.K. Ward, D.N.S.
Kerr, University of Newcastle Upon Tyne (England), Hospital
Nacional "Valdecilla", Santander, Spain. Osteomalacia (OM) and
hypoparathyroidism are associated with aluminium accumulation in
patients with chronic renal failure. This association might be due to
aluminium deposition in parathyroid gland. However it cannot be
excluded that aluminium might accumulate in bone as a result of low
bone formation. We examined the biochemical changes (Ca2, phos-
phate, alkaline phosphatase, iPTH, aluminium, and magnesium) and
bone histology in 17 uremic patients before and after (4—44 months
mean 19 months) parathyroidectomy. The bone biopsy obtained before
VFX showed histological features of severe osteitis fibrosa, and in one
case osteomalacia was also present. A significant decrease was ob-
served after PTX in Ca x P product, alkaline, phosphatase, iPTH (P <
0.001) with persistence of woven bone. The bone aluminium staining
was positive in 2 patients (12%) before the surgical procedure and in 8
cases (47%) after parathyroidectomy without significant differences in
the oral aluminium intake between both periods. Two out of the sixteen
patients without osteomalacia before PTX developed OM Al+ after the
operation (one case was dialized with softened water following PTX).
We conclude that PTX is an effective treatment of severe osteitis
fibrosa, although it may increase the risk of induced bone disease
aluminium.
The functional reserve of the hypothalamus—pituitary—gonodal axis
in the uremia: Therapeutical implications. A. Martin Malo, P. Benito,
M. Castro, E. Herrero, A. Calvo, L.G. Burdiel, D. Castillo, P. AUama,
Hospital Regional "Reina Sofia", COrdoba, Spain. Since the hormone
plasma level disorders of this axis have been reported repeatedly, this
work deals specifically with the functional glandular secretory reserve
looking for further therapeutic strategies. Three groups of males were
studied: 34 on hemodialysis (HD), 8 kidney transplants (KT) with
normal renal function and nine normal controls (C). Acute stimulation
tests were carried out with LH-RH and TRH measuring FSH, LH and
prolactin (PRO) at 0, 20, 60 and 120 minutes. In addition chronic
stimulation tests were performed with chomiphene (CLO) 100 mg/day
x 7 days; completing it with a bromocriptine suppression test. Testos-
terone (TES) reserve was studied in all cases. On HD we obtained a
functional reserve of FSH, LH and PRO after the acute stimulus,
significantly lesser in comparison with those of C (P < 0.001); in KT this
reserve was similar to C. However the chronic stimulus showed
statistically comparable results in all three groups: an increase of FSH
and LH. The suppression showed a good TES response. The CLO on
HD was associated with a normalization of TES, which was previously
lower (P <0.001). In addition, the CLO decreased the PRO blood levels
of HD patients. These overall results were reproduced in a group of
patients sequentially studied during HD and after KT, The uremia
deteriorates the functional secretory reserve of the pituitary gonadal
axis (acute stimulus). This disorder is reversible and independent of
significant organic injury (chronic stimulus and KT). The CLO could be
a new alternative treatment for uremic hypogonadism since it restores
the TES blood levels to normal.
Alveolar gas exchange and pulmonary hemodinamics during hemodi-
alysis. D. Castillo, R. Guerrero, M. Jaraba, C. Baamonde, M. Barrera,
A. Salvatierra, F. Gonzalez, J.L. Pujol, P. AIjaina, Hospital Regional
"Reina Sofia," Córdoba, Spain. Recent works in animals have docu-
mented histological changes in the lung during hemodialysis (HD)
affecting the pulmonary capillaries and alveoli in relation to membrane
biocompatibility. However their clinical and functional consequences
have not been determined. We have studied the relation between the
pulmonary gas exchange and pulmonary hemodynamics in an experi-
mental model of HD. Twenty normal, non-uremic dogs were studied;
eleven on HD with cuprophane membrane and nine with poly-
acrylonytrile for 60 minutes under anesthesia and assisted ventilation
(no hypoventilation) with Fi 02 0.5. The following parameters were
studied at 0, 3, 5, 7, 10, 15, 20, 30, 45 and 60 minutes; arterial, venous,
and mixed venous blood gas, intrapulmonary shunting (Qs/Qt), alveolar
arterial oxygen gradient (Aa02), pulmonary arterial pressure (PAP),
precapilary gradient (PCG) arteriolar pulmonary resistances (APR) and
consumption of 02.
0' 15' 30'
CU AN CU AN CU AN
P02 231 225 l70 190a.b l47 161a,b
Qs/Qt
Aa02
12
87
12
95
l7
142a
14bl3l 7a7a 13b
PAP 21 19 23 19b 22 17b
PCG 5.7 4.6 8.0k 50b 6.5a 38b
APR 239 279 367k 285b 385 288b
P < 0.05: a o' vs. 15 and 60', b CU vs. AN
HD-associated hypoxemia is, among other factors, related to a signifi-
cant ventilation/perfusion mismatch. Pulmonary hemodinainic changes
depend on the type of membrane used (APR increase). Both phenom-
ena are involved in the pulmonary dysfunction observed during con-
ventional HD.
Cardiovascular effects of hemodialyis: study In nonuremic animals. M.
Jaraba, D. Castillo, R. Guerrero, A. Martin—Malo, F.M. Gonzalez, J.
Gomez, J. Mallol and P. AUama, Hospital "Reina Sofia", Cordoba.
The cardiovascular effects and hemodynamic response during conven-
tional hemodialysis (HD) in healthy subjects have not been studied.
Only experimental works could elucidate the relevance of the uremic
state and the procedure itself. The present study was undertaken in 7
normal nonuremic dogs, excluding additional circumstances which
determine cardiovascular instability during HD: isovolemia (ultrafiltra-
tion monitor), isonatremia and isocalcemia (adjusted dialysis fluid),
isotermia (thermistor) and absence of hypoxemia (mechanical ventila-
tion). Every 15 mm until 90 the following parameters were measured:
mean arterial pressure (MAP); intraarterial, peripheral vascular resis-
tance (PVR); cardiac output, cardiac index (CI) and stroke index (SI),
thermodilution, left stroke work index (LSWI); acetate blood levels
(Ac); enzymatic, plasma volume (PV), albumin 1-131; and other.
0 mm 15 mm 45 mm 90 mm
MAP 120 115 l03 91"
PVR 49 38" 39 38
CI 2.5 3.1" 2.6 2.5
SI 23 27 23 l9
LSWI 35 37 27" 22"
Ac 0 4,2a 8.5" 59"
PV 1.9 2.0 1.9 1.9
The HD procedure induces a decrease in PVR which is initially
compensated by an increase in CI and SI. Later myocardial contractil-
ity is depressed as documented by a significant decrease in LSWI. Both
factors, peripheral vasodilatation and negative inotropic effect, are
mediated by acetate. The cardiovascular adaptation to HD in healthy
subjects is similar to that observed during treatment of uremic individ-
uals.
Abnormalities of thirst regulation In patients with chronic renal failure
on hemodialysis (Cre-HD). A. Martinez Vea, C. Garcia, J.A. Oliver, J.
a (P < 0.05)
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Gaya, F. Rivera, C. Richart, Section of Nephrology, Service of Internal
Medicine, Hospital Juan XXIII, Tarragona, Hormonal Laboratory,
Hospital ClInico, Barcelona, Spain. In order to determine whether the
thirst mechanisms are altered in patients with CRF-HD, we studied two
groups of nondiabetic patients with CRF-HD: 4 with an average weight
gain between dialysis of more than 5% of dry body weight (Group I), 5
with less than 3% (Group II), and a group of 6 healthy subjects (Group
III) were submitted to an infusion of hypertonic saline serum for two
hours. After the infusion the subjects had free access to water for 60
minutes. Thirst was evaluated by a visual—analogue rating scale.
Despite similar increments of effective plasma osmolality during the
saline infusion, patients of group I were thirstier than groups II and III
(P < 0.005 and P < 0.01, respectively). Changes in thirst ratings were
similar in group II and III. During the drinking period, patients of group
I drank more than group 11(14.2 5.7 vs 5.3 3.7 mI/kg respectively,
P <0.02). Throughout the study, plasma angiotensin II and vasopressin
levels were higher in group I and II than in the control group, but there
were no differences between the uremic patients. There was no corre-
lation between plasma angiotensin II concentrations and interdialytic
weight gains. Vasopressin secretion during saline infusion was similar
in group I and II. Our results indicate that some patients with CRF-HD
manifest inappropriate hyperdipsia probably due to resetting of the
thirst osmostat. This abnormality is not mediated by angiotensin II or
vasopressin and may contribute to the greater weight gain which these
patients show between dialysis.
Hypertonic hemodialysis (HD) and endogenous middle molecules (MM)
removal. M. Garcia, M. Carrera, P. Arrizabalaga, E. Merola, J. Pons,
X. Company, L. Revert. It is known that hypertonic methods in HD
allow cellular dehydration. The aim of this study was to evaluate the
efficiency of hypertonic HD in endogenous MM removal. In 10 patients
the extraction index and mass transfer for MM were determinated on
conventional and hypertonic HD. The same patients underwent both
types of HD, using a cuprophane membrane. Dialysis length was 4
hours in all cases, Hypertonic HD done by perfusing 545 mEq of Cl Na
for the first 150 minutes of HD and using a dialysate containing 130
mEq/liter of Na in order to avoid a positive Na balance. Conventional
HD was done by a 139 mEq/liter Na dialysate. MM were determined by
gel filtration with Sephadex G-15 and ion exchange (DEAE Sephadex
A-25). The ultrafiltration volume in conventional HD was 3033 886 ml
and in hypertonic HD 2744 768 ml. The mass transfer of MM in
hypertonic HD was significantly higher than conventional HD: peak
2.2.: +30.4%, peak 2.3.: + 124.1%, and Z peak 2: +44.8%. The initial
levels of plasma MM and the extraction index in both groups were
same. Our results confirm that hypertonic methods increase the re-
moval of MM without changing the extraction index. The increase in
MM removal on hypertonic HD could be attributed to MM mobilization
from intracellular volume.
Exogenous interleukin-2 (IL-2) effect on uremic lymphoblastogenesis.
M. Gonzalez, A.L.M. de Francisco, J.G. Cotorruelo, E. Canga, S.
Sanz de Castro, M. Arias, Servicio de Nefrologia, Hospital Valdecilla,
Santander, Spain. The basis of cellular immunodeficiency in uremic
patients is not well known; a decreased response to mitogens has been
recognized at in vitro experiments. In order to analyze the exogenous
IL-2 supplementation effect on that deficiency we have undertaken the
following study: from 13 patients and 9 healthy controls periferal blood
lymphocytes (PBL) were cultured with PHA (X 3): (a.) with previous
monocytes removal; (b.) after exogenous IL-2 supplementation (30:
U/mI); (c.) in uremic serum (US); (d.) with indomethacin (IND).
Results. (1.) IL-2 addition to uremic lymphocytes cultures normalizes
blastogenic response (P < 0.001). (2.) Monocytes removal also ampli-
fies uremic lymphocyte proliferation (P < 0.001) (3.) In cultures without
monocytes the IND does not produce additional effect. (4.) Without
monocytes the IL-2 does not exert any action except in cultures with
US (P < 0.02). Conclusions. (1.) IL-2 addition normalizes "in vitro"
uremic lymphoblastogenesis. (2.) In cultures with monocytes removal
IND does not produce any additional effect. (3.) There are not differ-
ences among cultures with IL-2, with IND or without monocytes,
suggesting a similar way of action on immunoregulatory mechanism.
Inhibitory factors of lymphoblastogenesis of uremic serum (US):
Depuration capacity of different membranes. M. Gonzalez, A.L.M. de
Francisco, E. Canga, P. Morales, L. Ruiz, A. Zubimendi, M. Arias,
Servicio de Nefrologia, Hospital Nacional "Valdecilla", Santander,
Spain. The immunosuppressive capacity of US has been ascribed to
retained substances like middle molecules (MM). We have studied the
acute changes induced by different dialysis membranes, cuprophan
(CU), polisulphone (PS), AN-69 and peritoneum (CAPD) on the inhib-
itory capacity of US over PHA induced blastogenesis of normal
lymphocytes. Materials and methods. Patients were 3 M and 2 F on
chronic hemodialysis. Each one received 3 consecutive dialysis with
CU, PS and AN-69, and 2M/3F on CAPD. Middle molecules were
determined from serum and ultrafiltrates (UF) by Sephadex G-15 and
high performance liquid chromatography (HPLC). Cultures: Peripheral
blood lymphocytes from 10 healthy donors were cultured with PHA
adding in different replies: (a) predialysis US; (b) postdialysis US; (c)
ultrafiltrate obtained by convective transport, and in CAPD patients, (d)
US and (e) dialysis bag solution after peritoneal exchange. Results. (I.)
US from patients on hemodialysis inhibits lymphocyte proliferation
without any change after dialysis, whatever dialysis, whatever the
membrane was used (P < 0.001). (2.) The ultrafiltrate does not inhibit
the cultures. (3.) No inhibitory effect is observed with US and with
dialysis solution from patients on CAPD in a chronic way. Conclusions.
The inhibitory effect on lymphoblastogenesis of uremic serum is not
modified after dialysis with CU, PS or AN-69. CAPD seems to depurate
the serum of these patients from the mentioned inhibitory factors.
Calcitonin (CT) and hyperparathyroidism (HPT) in dialysis (D) and
after renal transplantation (RT). A. Figuereo, R. Perez—Garcia, MA.
Alvarez de Lara, M. Sanchez, J. Luño, F. Valderrabano. Hospital
Provincial de Madrid, Madrid, Spain. The relevance of CT in renal
osteodystrophy is uncertain. To assess the possible influence of CT on
Ca metabolism in D and renal transplanted patients: CT (RIA-IRE),
PTH (35—84 RIA), Ca, P and alkaline phosphatase were mea-
sured twice a year. Eighty out of 100 adult patients on D maintained
high serum levels of CT. In 71 patients on hemodialysis (HD) during 2
years, without any treatment with Vit. D, progression of HPT was
found and CT decreased significantly, so PTH/CT ratio increased from
0.8 to 1.86. The long—term treatment (2 years) with calcitriol (CC) in 59
patients on HD prevented the progression of HPT and increased CT
levels P < 0.01. The patients who developed hypercalcemia in relation
to CC treatment did not modify their PTH/CT ratio while this ratio
decreased significantly in those who remained normocalcemic. In
contrast with HD patients the mean serum level of CT in 8 patients on
CAPD was normal and did not change with CC treatment, Thirty—five
adult RT recipients with normal renal function for more than 6 months
(6 to 102 months) were also studied. CT levels post-RT normalized
before PTH, which remained elevated in some cases for several years.
We have not found correlation between CT and PTH neither CT and P
post-RT but there were significant correlations between Ca and PTH (N
= 47, r = 0.38) and better for Ca and PTH/CT ratio (N = 47, r = 0.47).
Hypercalcemic patients with HPT post-RT had lower CT levels than
those normocalcemic with similar PTH, P < 0.05. Conclusion. CC
treatment increases CT levels in HD patients, in CAPD CT levels are
lower and do not change. CT have a role in maintaining Ca levels pre
and post RT. Inappropriately low levels of CT could represent a failure
to secretion CT.
Response to deferoxamine (DFO) in hemodialysis patients with severe
non-iron deficiency anemia. P. Arrizabalaga, M. Carreras, M. Pocino,
M. Garcia, C. Piera, f.M. Pons, L. Revert, Servicios NefrologIa y
Medicina Nuclear, Hospital Clinic, Barcelona, Spain. Anemia related
to aluminium (Al) toxicity improves after treatment with chelating
agents. We have evaluated the response to DFO in severe non-iron
deficiency anemia. Five patients on hemodialysis for 8.4 4 (± SD)
years and free of bleeding, infection and surgery during the last year
have received DFO (50—60 mg/kg) twice weekly for 11.5 2.9months.
Hematological parameters, plasma clearance (T '/2) and globular uptake(U) of 59Fe-citrate, and mean red cell survival with 51Cr-sodium
cromate (T 50) before and after DFO were:
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Pre Post P
Transfusions 1.12 0.20 (5_7)a 0.62 36 (l_5)b < 0.01
Hematocrit (%) 22.5 4.6 24.5 5.4 NS
Hemoglobin (g/dl)
MCV (p3)
7.6 1.7
94.6 5.3
8.4 1.8
94.2 3.1
NS
NS
MCH (pg) 31.6 1.9 31 1.3 NS
Reticulocytes (%) 1.08 0.4 1.54 0.6 NS
Iron (g/d1) 161.2 34 196.6 56 NS
Ferritin (ngldl) 2827 1430 2232 1363 <0.05
T /2 (mm) 196 31.4 147.2 34.3 <0.05
U (%) 50.2 3.3 59.7 13.9 NS
T 50 (days) 22.6 1.2 21.2 6 NS
SD of the number of packed RBC units transfused monthly and
range of the number of transfusions during the year before treatment at
Hct of 17.7 2,9%b At Hct of 17.4 1.4 (NS)
Serum Al rose 107.6 37 ng/ml to 197 99.7 nglml 48 hours after a
single dose of 2 g DFO, and decreased to 66.8 27.6 ng/ml (P < 0.05)
after treatment. Alkaline phosphatase and serum levels of C-PTH and
N-PTH increased in individual patients. Conclusion. The need for
transfusions decreases significantly in patients with severe non-iron
deficiency anemia treated with DFO, presumably by enhancing
erythropoiesis.
Monoclonal antibody analysis of cellular infiltrate In human glomeru-
lonephritis. P. Arrizabalaga, E. Mirapeix, L. Revert, Servicio Nefro-
logia, Hospital Clinico, Barcelona, Spain. Monocytes—macrophages
(Mo-Ma) play a role in the pathogenesis of experimental glomerulone-
phritis (G). Mononuclear cells were identified within the glomerular and
interstitial infiltrate in 64 renal biopsies (54 G, 10 nonG) by indirect
immunofluorescence using monoclonal antibodies to cell surface anti-
gens: EDU-l (HLA-DR), Cris-l (total T), OKT4 (helper/inducer T) and
OKT8 (suppressor/cytotoxic T), and by demonstration of nonspecific
esterase activity (Mo-Ma). Intraglomerular both T cells and Mo-Ma
were only present in biopsies with G, and more frequently in prolifer-
ative G than in nonproliferative G (X2 = 4.12, P < 0.05 and X2 = 8.82,
P < 0.005). Mo-Ma was significantlydetected in biopsies with diffuse
intra- or extracapillar proliferation (X2 = 4.68, P < 0.05), C3 (X2
4.21, P <0.05), and fibrinogen (X2 = 3.84, P < 0.05) immune deposits;
and it was higher in biopsies which showed also T cells than in biopsies
without the latest, 0.35 0.66 ( SD of number of Mo-Malglomerulus)
versus 0.16 0.32. There were significant differences in DR cells (X2
= 5.5, P < 0.02), T cells (F = 3.37, P < 0.005) and Mo-Ma (F = 2.42,
P <0.05) infiltrating the interstitium between the types of renal disease.
The cellular infiltration was higher in G with diffuse intra- or extracapil-
lary proliferation than in the rest. A correlation was found between the
intensity of T cells and DR cells (r = 0.63, P < 0.001), and Mo-Ma (r
= 0.38, P < 0.02) that contributed to interstitial infiltration in the G. In
conclusion. (1.) the glomerular hypercellularity in proliferative G is in
part due to infiltration by both monocytes—macrophages and T cells, (2.)
the presence of both cellular types in the G suggest possible cellular
immune interactions in situ.
Hemodlalysis without anticoagulation. A. Perez, L. Garcés, J.
Sanchis, R. Moll, f.M. Escobedo, Department of Nephrologie, Hospi-
tal General, Valencia, Spain. In hemodialysis (HD) the use of heparine
(H) for extracorporeal anticoagulation is very common. Occasionally,
patients to be tracted with HD show bleeding risks: therefore
anticoagulation increases the risks and its dangerous consequences. We
have 187 HD without H in 22 patients affected with chronic renal failure
(CRF, 10 females and 12 male) with ages between 29 and 74, during a
period of 18 months. All of them had clinical symptoms of bleeding. The
HD have been carried out with a capillary dialyzer with cuprophan
membrane. Before starting the HD the lines and the dialyzer were
washed with a mixture of 1 liter of physiologic saline solution (0, 9%)
and 6.000 U of heparine, There was no administration of H during the
HD. In 10 patients, the blood analysis before and after the dialysis
included: urea, uric acid, creatinine, K, P, RBC, leucocytes, platelets
and thrombogenesis study. These results were compared with the
results of 10 patients in which H was administrated during the HD. In
the comparison of the results between these two groups, we could
appreciate that the HD without H has similar efficiency as the HD
without H (decrease of the urea, uric acid, creatinine, P, K at a p 0.0001
in both modalities). In 11 HD (5, 8%) the dialyzer was coagulated and
in 35 (18.7%) the venous line had to be changed. Transfusion was not
necessary in any case. From this study we conclude that the HD
without H, with a capillary dialyzer with cuprophan membrane in CRF
patients with bleeding risks, is an effective therapeutic method, in
which the adverse effects are less than the risks which can occur in case
of administration of anticoagulants.
Osteocalcin levels in uremic patients: Influence of dialysis type and
short—term 1-25(OH)D treatment. M.E. Matinez, J.L. Miguel, R.
Selgas, C. Pedro, G. Balaguer, F. Escuin, L.S. Sicilia, F. Llach,
Biochemistry and Nefrology Services, H. "La Paz", Madrid, Spain. In
order to evaluate the influence of dialysis type and the effects of
l-25(OH)D on osteocalcin we studied 93 uremic patients (pts); 24 on
hemodialysis (HD); 40 on CAPD; 29 had chronic renal failure (CRF),
CCr <20 ml/mn and not yet on dialysis. All (pts) were younger than 65
years and there were not significant differences between the ages of the
groups. All blood samples wre obtained in winter—spring in order to
avoid the effects of the seasons on 25(OH)D. All the (pts) were residents
in the same geographical area. Thirty—one pts (21 on CAPD and 10 on
HD) were treated with 1 ,25(OH)D (0.12—0.25 meg) orally for more than
three months. In the morning prior to dialysis all pts had blood drawn
under fasting conditions. The following parameters were determined:
Ca, P, AP, PTH C-terminal (35—84) (IRE), 25(OH)D (Protein binding
after HPLC) (Bulhman) and osteocalcin (0.C.) (INC). Results. The OC
levels correlated with the PTH, AP and 25(OH)D and did not correlate
with Ca and P. The Ca and P levels were similar in the 3 groups of pts
(HD, CAPD and CRF). The CRF and CAPD pts had lower AP levels
than the HD group. CRF pts had lower OC and PTH levels than the HD
group. OC 24 13 vs. 36 19, PTH 21 8 vs. 30 14. The CAPD
group had lower 25(OH)D (10 5) than HD (19 12) and CRF (20
15) groups. CAPD pts had lower OC (23 17) than HD (35.9 18) but
PTH levels were similar. Pts treated with 1 ,25(OH)D for more than 3
months had higher OC levels (32.8 19) than untreated pts (24 15).
Ten pts from the CRF group were treated for 1—2 months with
1 ,25(OH)D (0.25—0.5 meg/day) and 13 pts (6 on CAPD and 7 on HD)
received a single oral dose (2 meg). Both groups had a significant
increase in OC levels, with no change in PTH levels. The mean OC
peritoneal loss was 4.9 1.5 ng/ml with a mean saturation index of 28
10%. Conclusions. OC was lower in CRF and CAPD groups than in
HD, and was significantly correlated with PTH, 25(OH)D and AP. In
addition, it increased with the short term and acute administration of
I ,25(OH)D. The lower levels in CAPD can be influenced by the
peritoneal losses.
Multicenter CAPD registry: Report to 31-12-1985. J. Conde, R.S.
Virgen de la Salud, Toledo, Spain. The registry commenced in 1981,
collecting progress reports and data of patients (P) on CAPD treatment
in the participating centers (C). CAPD use from Sept. 1979: 1304 P have
been treated in 57 C, of which 8 had floP on 3 1-12-85, 1 did not send in
data, and 48 were treating 597 P (15, 7 PMI) with wide variation among
them: (P/C = 22.9 27.3), and among the self-governing regions (max
37.5, mm 4.9 P PMI). The number of P starting has diminished: 1983 =
309, 84 = 303, 85 = 274. Patients: M 54%, F 46%. Older than 65
younger, 18%. Commonest nephropathy was secondary multisystemic
diseases, 24%. Followup: /P = 18 months (M) (1—64). Patients con-
tinuing CAPD 597; deaths 230; transplanted 90; transferred to other
techniques 365; recovered 11 and lost to follow up 11. Technical
survival rate year 1: 83%, 2nd: 68%, 3rd: 56%, 4th: 48%. Main cause of
abandonment was peritonitis (58%). Mortality: 230 P died "in" and 88
"after" CAPD. Survival rate "in CAPD" first year was 89%, 2nd 78%,
3rd 66%, and 4th 63%. Main causes of death were cardiovascular (38%);
secondary infections, (26%). In 22% a death/CAPD relation was found.
Assessment: Good: 66% of all P. Doubtful : 20%. Bad: 14%.
Iron (Fe) gastrointestinal (C-I) absorption: Influence of Aluminium
hydroxide (Al(OH)). M. T. Allede, 1. Fernandez—S oto, M.J. Fernñdez
Menéndez, M.C. Diaz de Greñu, M. Naves, J.M. Arribas, J.B. Can-
nala, Hospital General de Asturias, Facultad de Medicina de Oviedo,
Asturias, Spain. Al(OH)3 could interfere with erythropoiesis either
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through its direct effect on the bone marrow or impairing Fe G-I
absorption. Therefore the aim of this study was to evaluate the likely
influence of Al(OH)3 on Fe59G-I absorption in rats with normal renal
function. We studied 50 male, adult Wistar rats in three successive
steps. All studies were done throughout 10 days maintaining the rats in
metabolic cages. On each step the rats were divided in two groups:
Group A received only Fe59. Group B received Fe59C1 + Al(OH)3.
These compounds were administered through gastric-oesogagic cathe-
ter during two consecutive days in order to avoid the influence of
physiological variations in Fe absorption. Throughout the three steps
(20, 15 and 15 rats, respectively) we modified the dose of the carrier
SO4Fe: (4-20 mg); the dose of ascorbic acid: (40-200 mg) and the dose
of Al(OH)3 in Group B: (30-100 mg), keeping the dose of Fe59CI (60
MCi). The Fe59Cl absorption was investigated using two different
isotopic methods: I) Total body counter, II) Residual radioactivity of
Fe59 in feces. Using method I, the % of Fe59 absorption ranged from
18.1 to 26% in Group A and from 15 to 26% in Group B. With method
II they ranged from 8.2 to 8,6% in Group A, and from 8.6 to 9.3% in
Group B. These findings suggest that in rats with normal renal function
the administration of Al(OH)3 in dose equivalent to those received by
dialysis patients, does not seem to interfere with Fe G-I absorption.
Prevalence and causes of osteomalacia (OM) in uremic patients before
chronic dialysis (CD). A. Torres, V. Lorenzo, J.C. Rodriguez, L.
Hernandez Nieto, L. Diaz Flores, Nephrology Servic, Htal. Gral.
ClInico, Tenerfe, Canary island, Spain. There is little doubt that the
common cause of progressive OM in patients on regular hemodialysis is
aluminum intoxication. However, the prevalence and causes of OM in
urenuc patients before CD remains controversial. In order to clarify this
problem we have studied bone histomorphometry and biochemical data
of 51 unselected uremic patients with GFR <8 mI/mm just before CD
(43 16 years). A total of 13 (25%) suffered OM (7 pure and 6
associated to osteitis fibrosa (OF)). A positive Al3 stain at osteoid/
mineralized bone interphase was detected in 3 cases of pure OM. The
results are summarized in the Table:
CaXP A.P. C03H TBV ROY F Al3
Mild 55.3± 239.7± 21.2± 21.1± 6.1± 0.2± 0
(N = 26) 12.5 155.9 3.5 3.4 2.7 0.2
OF 53.7± 398.1± 21.6± 23.7± 10.9± 4.1± 0
(N = 12) 12.2 187.3 4.7 7.6 2.5 8.2
OM 46.3± 362.6± 17.6± 28.6± 23.2± 1.0± 3
(N= 13) 15.7 235.9 8.1 7.8 4.9 0.9
TVB, travecular bone volume; ROY, relative osteoid volume; F, %
peritrabecular fibrosis.
OM was associated with severe acidosis (C03H <17 mEq/liter) (X2 =
4.6, P < 0.05) and a low CaXPO4 (<34 mg/dl) (X2 = 4.4; P < 0.05). In
summary: (1.) Although uncommon, aluminum—related OM may appear
before CD, probably as the result of the oral intake of (OH) 3A1. (2.)
Severe acidosis and a low CaXPO4 product are imortant factors in the
genesis of OM in this situation.
Incidence of osteosclerosis (OS) and osteoporosis (OP) in renal osteo-
dystrophy (ROD). V. Lorenzo, A. Torres, M. Pestano, A. Rodriguez, L.
Diaz, Htal. 'V. de Candelaria", Fac. Medicina, Canary island,
Tener(fe, La Laguna, Spain. The morphologic manifestations of ROD
include combinations of osteitis fibrosa (OF) and osteomalacia (OM) in
a setting of reduced (OP), normal or increased (OS) bone mass. The aim
of the present study was to know the incidence of OP and OS in ROD.
Quantitative histomorphometric analysis of bone was evaluated in
transiliac bone biopsy from 101 unselected uremic patients, 53 non-
dialyzed and 47 undergoing maintenance hemodialysis. We defined Os
and OP in terms of trabecular bone volume values observed in our 18
control subjects, to include patients with values exceeding the control
means pIus 2 SD, that is values >30% and <16%, respectively. Biopsies
were classified in 4 histologic groups: Mild, OF, OM and Mixed forms
(OF + OM). Osteosclerosis was relatively common in our series (18%).
It was more frequent in hemodialysis patients, especially associated
with advanced forms of OF and/or OM. The more severe cases were
seen in pure OM due to hypophosphatemia. Osteoporosis was an
unusual component of ROD (8%) appearing more frequently in non-
dialyzed uremic patients, related to mild forms of ROD. Diabetic
patients had a higher incidence of OP (X2 = 7.84, P < 0.01). Although
uncommon, OP may have important clinical consequences. From 120
renal transplanted patients, we found bone complications in 3, all of
them having pretransplant OP.
Treatment of hyperkalemia in renal failure: Salbutamol versus glocuse
and insulin. X.M. Lens, J. Montoliu, A. Cases, L. Revert, Nephrology
Service, Hospital ClInic, Barcelona, Spain. Beta 2 adrenergic stimula-
tion with salbutamol enhances intracellular potassium (K) uptake in
renal failure. To evaluate if this effect is potentially useful in the
treatment of hyperkalemia, we studied 3 groups of patients with renal
failure and hyperkalemia, (serum K >6 mmol/liter) similar in age, serum
creatinine and pretreatment serum K. Group A (N = 20) received
salbutamol 0.5 mg i.v. in 15 mm; group B (N = 10) received glucose 40
g i.v. plus 10 units of regular insulin i.v. in 15 mm, and group C (N = 10)
received both, salbutamol 0.5 mg i.v., glucose 40 g i.v. and regular
insulin 10 units iv. over a period of 15 mi Serum K was recorded at
30, 60, 180 and 360 mm after adminstration of treatment. Although all
treatments induced mean decrements in serum K that ranged from
—0.49 0.14 to —1.48 0.2 mmol/liter, patients from group C showed
a significantly higher decrement in serum K when compared to group B
at 60 (—1.48 0.2 vs. 0.99 0.1 mmollliter, respectively, P < 0.01) and
180 mm (—1.2 0.17 vs. 0.67 0.12 mmol/liter, respectively, P <
0.05). There were no significant differences between groups A and C.
Patients from group C exhibited more tachycardia and more prolonged
hyperglycemia than those from group B, but all treatments were well
tolerated. Therefore salbutamol enhances the K-lowering effect of a
glucose and insulin infusion and is a worthwhile contribution to the
treatment of hyperkalemia secondary to renal failure.
Types of renal involvement in infectious endocarditis. J.M. Campistol,
J. Montoliu, f.M. Miro, A. Torras, L. Revert, Nephrology and infec-
tious Diseases Services, Hospital Clinic, Barcelona, Spain. From 1979
to 1986, 163 episodes of infectious endocarditis were diagnosed at a
single center. Of these, 40 patients had renal involvement. Two main
types of renal involvement could be distinguished: type A (27 patients,
67.5%) was characterized by isolated renal failure (serum creatinine
>1.5 mg/100 ml) without proteinuria or hematuria, and type B (13
patients, 32.5%) was characterized by proteinuna (>1 g/24 hr),
hematuria, and renal failure. Renal involvement type A was attributed
to Pseudomonas sepsis in 1 case, cardiogenic shock in 1 case, combined
vancomycin and aminoglycoside toxicity in 13 cases, isolated amino-
glycoside toxicity in 11 cases and to amphotericin B nephrotoxicity in I
case. Renal histopathologic examination could be performed in 7
patients from type A and in 8 patients from type B. In type A, histology
showed acute tubular necrosis (6 of 7), cortical necrosis (I of 7) and
presence of microabscesses in the renal parenchyma (2 of 7). In type B,
the main histologic findings were: diffuse proliferative glomerulonephri-
tis with C3 deposits (6 of 8), extracapillary proliferative glomerulone-
phritis with negative immunofluorescence (1 of 8), and focal prolifera-
tive glomerulonephntis with mesangial IgA and fibrinogen deposits in
an additional patient with Henoch—Schönlein purpura. There was no
correlation between the nature of the causative microorganism, the
localization of endocarditis or the existence of drug addiction with the
development of glomerular disease. Ten of the 27 type A patients and 3
of the 13 type B patients died. In both cases, the mortality was higher
than the total mortality of the series. We conclude that: (I.) renal
involvement occurs in approximately 25% of cases of infectious
endocarditis; (2.) nowadays antibiotic—induced nephrotoxicity predom-
inates; (3.) among the various types of glomerulonephritis associated to
infectious endocarditis it is of note the existence of isolated cases of
Henoch-Schönlein purpura; and (4.) renal failure in infectious
endocarditis carries a poor prognosis.
Usefulness and mechanisms of action of DDAVP in the treatment of
uremic trombopathy (UT). A. Cases, f.M. Campistol, G. EscolO, A.
Ordinas, J. Lopez, R. Castillo, L. Revert, Nephrology and Hemother-
apy Services, Hospital Clinic i Provincial, Barcelona, Spain. DDAVP(I desamino 8 D arginine vasopressin) is known to increase plasma
levels of Factor VIII related activities and has proved to be useful in the
treatment of UT. We have analyzed the efficacy, mechanisms of action
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and adverse effects of DDAVP in the treatment of UT. Methods. We
studied 11 patients with end—stage renal disease with bleeding tendency
and/or severe impairment of platelet function assessed by prolonged
bleeding time (BT) and abnormal aggregation tests (AT). DDAVP (0.4
g/kg/min) was infused in 20 minutes. Platelet adhesivity (PA), BT, AT
and platelet interaction with subendothelium (Baumgartner perfusion
tests) were measured before, and one and six hours after the infusion.
Perfusion experiments were also performed with addition of 1 U/mi of
purified vWF to uremic blood in order to study the role of this factor in
the improvement of UT treated by DDAVP. Results. (I.) Basal BT (16.9
mm) was significantly shortened in the first hour (9.6 mm, P = 0.05), but
no differences could be found in the sixth hour (14.9 mm). (2.) PA varied
from 35.6% (basal) to 60.2% in the first hour (P < 0.05) and 38.1% at the
sixth hour (NS), (3.) Platelet aggregation (RIPA and ADP-induced sixth
hour (NS). (3.) Platelet aggregation (RIPA and ADP-induced aggrega-
tion) didn't show marked differences along the experiment. (4.) Perfu-
sion experiments in the Baumgartner's camera showed an improvement
of platelet deposition in the first hour, running in parallel with BT and
PA. (5.) In vitro addition of 1 U/mI of vWF didn't modify the
parameters measured in the perfusion experiments. (6) Mean blood
pressure lowered 20 minutes after DDAVP infusion but recovered at
one hour after perfusion. One patient with diabetic dysauthonomy
developed severe hypotension. Conclusions. (1.) The administration of
dDAVP improves UT during the first hour, although its effect is
transient; (2.) Perfusion experiments were not able to confirm that this
improvement was due to increase in plasma levels of vWF; (3.)
Hypotension is the main adverse effect, it is usually slight, although it
deserves a careful follow—up.
Intervention of endogenous vasopressin in essential arterial hyperten-
sion (EHT): Blockade with DDAVP. A. Cases, X.M. Lens, A. Botey, J.
Gaya, L. Revert, Neprhology Service, Hospital Clinic i Provincial,
Barcelona, Spain. Previous studies have shown that although plasma
vasopressin (AVP) levels are normal in the EHT, there is a higher
pressor response to the exogenous administration of this hormone. The
vascular action of AVP is mediated by vascular (Vi) receptors. We
analyzed the effects of V1 receptors blockade with 1 desamino-8-D
arginine vasopressin (DDAVP) as an indirect method to study the
sensitivity of these receptors to the endogenous AVP. Methods. Eight
patients with moderate EHT and 6 control normotensive subjects of
similar age and sex were infused with incremental amounts of DDAVP
(5, 10, 20 and 40 ng/kg/min) in periods of 20 minutes each). Results: (1.)
The decrements of blood pressure were greater among patients with
EHT than normotensive controls at doses of 10 (P < 0.05),20 (P < 0.05)
and 40 ng/kg/min (P = 0.01). (2.) In the hypertensive patients there was
a strong correlation between basal mean arterial pressure and blood
pressure decrements (r = 0.95, P <0.001). (3.) The heart rate increased
similarly in both groups, except for the highest infusion rate where the
increase was higher among the hypertensive patients (P = 0.017). (4.)
The DDAVP infusion induced a significant increase of plasma renin
activity (P < 0.05) and norepinephrine (P < 0.025) in both groups and
a decrease of prostacyclin, reaching statistical significance in hyperten-
sive patients (P < 0.05). Conclusions. (1.) These results show that in
moderate essential hypertension there is a greater sensitivity to the
pressor action of endogenous AVP. This greater sensitivity is probably
due to a greater activity of the vascular receptor at AVP. (2.) In essential
hypertension the vascular sensitivity to AVP is directly proportional to
basal blood pressure levels. (3.) In the future the V1 antagonists of AVP
might be useful in the treatment of essential hypertension.
Desferoxainine—induced clinical neurotoxicity, ocular and auditive in
patients with chronic renal failure. A. Cases, J.M. Capistol, M.C.
Grino, F. Sabate, J. Montoliu, A. Torras, J. Lopez, L. Revert,
Nephrology, Ophthalmology and ENT Services, Hospital Clinic i
Provincial, Barcelona, Spain. We report 5 patients with chronic renal
failure (CRF) on hemodialysis (HD) that have shown ocular and
auditive toxicity as a complication of their treatment with desfer-
oxamine (DFO). Four patients showed ocular toxicity; the mean age
was 63.8 years, 1 male and 3 females that received DFO either as a
diagnostic test of aluminium (Al) accumulation (2 patients) or as a
treatment of Al accumulation (2). After receiving a mean of 3.2 doses of
DFO (range 1—7 doses, 2 g of DFO at the end of every HD session) the
patients complained of loss of visual acuity, dyschromatopsy and night
blindness (2). After DFO withdrawal all patients' symptoms improved
within one month. An ophthalmologic study could be done in 3 patients.
The Farnsworth test of 28 hues showed a tritanopy (alteration of the
blue—yellow axis) in all the cases, which suggests retinal damage. In 1
case we have found pigmentary deposits in the fundoscopic examina-
tion. Another 41-year-old patient started treatment with DFO because
of Al intoxication. An audiometric examination before starting the
treatment was normal. After receiving 38 doses (1 g of DFO at the end
of each HD session) she complained of progressive and bilateral
deafness. The audiometric exam demonstrated a severe neurosensorial
deafness that was completely reversible after withdrawal of DFO
treatment. Conclusions. (1.) The treatment with DFO can produce an
ocular or auditive toxicity in patients with CRF on HD, in some cases
in an acute form, suggesting individual idiosyncrasy. (2.) The ocular
toxicity is characterized by a loss of visual acuity and tritanopy, while
the auditive toxicity is characterized by neurosensorial deafness. (3.)
We emphasize the usefulness of the Farnsworth test and the fundoscop-
ic examination, as well as the audiometry as easy and precocious
methods for the detection of ocular and auditive toxicity, respectively.
Amyloid arthropathy In patients with chronic renal failure on hemodi-
alysis. J. Munoz Gomez, R. Gomez, E. Llopart, A. Cases, J. Lopez—
Pedret, L. Revert, Rheumatology and Nephrology Services, Hospital
Clinic i Provincial, Barcelona, Spain. Recently, an arthropathy has
been reported due to amyloid deposition in the synovia in patients with
chronic renal failure (CRF) on long—term hemodialysis program. We
report our experience with a group of patients with CRF on HD and
amyloid arthropathy. Fourteen patients with CRF on HD with persist-
ent articular involvement were studied. Amyloid was demonstrated in
the synovia and/or articular fluid (AF). A complete medical history,
articular examination and radiologic studies were performed. The mean
age of the group was 58 years, 10 males and 4 females. Mean time on
HD was 11 years and mean time from the beginning of the symptoms
since starting HD was 7 years. The initial symptoms were variable and
frequently multiple, prevailing the carpal tunnel syndrome (CTS) (6
cases), knee swelling (7) and shoulder pain (5). During the evolution
new symptoms appeared in: shoulders, knees, wrists, elbows and CTS.
The radiologic examination showed geodes of variable size in elbows,
knees, wrists, pelvis, ankles and shoulders. Three cases showed erosive
spondiloarthropathy. Only in the wrists radiologic alterations could be
found in asymptomatic joints. Amyloid could be demonstrated in the
synovia of the knees (7 cases), articular fluid (13 cases) and CTS
structures (8 cases). Amyloid depositions could not be found in subcu-
taneous abdominal fat specimens. The articular fluid showed mechan-
ical characteristics in the majority of cases: mean cell number 1400
cells/mm3 (range 100—9400). Conclusion. Amyloid arthropathy begins
towards the 7th year from starting HD and it is characterized by a clinic
polyarthropathy, generally well—tolerated that mainly affects shoulders,
knees, hands and CTS. Amyloid deposits could not be found in the
subcutaneous abdominal fat. The articular fluid showed mechanical
characteristics in the majority of cases with a mean cell number of 1400
cells/mm3.
Histochemical and ultrastructural analysis of platelets in uremic pa-
tients. G. Escolar, A. Torras, A. Cases, f.M. Campistol, M. Garrido, A.
Ordinas, J. Lopez—Pedret, L. Revert, Servicio de Nefrologia, Servicio
de Hemoterapia, Hospital Clinic i Provincial, Barcelona, Spain. The
impairment of platelet function in the uremic patient has been widely
studied but the intimate nature of the mechanisms of this alteration
remains unknown. In the present study we have analyzed the
ultrastucture of platelets from uremic patients in an attempt to find
morphological changes that could explain the abnormalities observed in
platelet function. The study was carried out in 5 patients whose uremic
thrombopathy was evidenced clinically but also confirmed with labora-
tory tests: prolonged bleeding time, decreased platelet aggregation and
defective platelet deposition on subendothelium (Baumgartner perfu-
sion method). Conventional methods were used for samples processing.
The number of granules with dense bodies (DB) and granules a were
morphometrically quantitated. The endogenous peroxidase activity
(PPO) was determined by means of an enzymatic reaction and GPI at
the membrane level was localized with an immunogold method, the
membrane level was localized with an immunogold method. Results
obtained are summarized in the Table:
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DP platelet
section
granules a
platelet section PPO GPI
Controls 1.1 0.4 8.8 5.1 + +
Patient 1 1.1 0.3 7.9 5.1 + +
Patient 2 0.8 0.3 6.4 4.5 — +
Patient 3 1.1 0.4 8.0 5
Patient 4 1.0 0.3 8.6 4.8 + +
Patient 5 0.9 0.3 6.7 4.2 + +
In conclusion, although no abnormalities were found at the membrane
level, there was a statistically significant decrease in the number of
cytoplasmatic granules and also a diminished enzymatic activity in
several uremic patients. These alterations would explain the defect in
storage and release of granule content observed by other authors.
Blood transfusions (BT) and lILA in cadaver renal transplants (CRT)
with cyclosporin (CsA). M. Gonzalez—Molina, M. Cabello, P. Aranda,
M.A. Frutos, B. Ramos, F. Gil—Cepeda, E. Lopez de Novales, S.
Nefrologla, Hospital Regional Carlos Haya, Málaga, Spain. One
hundred patients were studied (64 males) who were transplanted
between VI-84 and VII-86. Average age was 34.8 12 years; 7 were
retransplants. None of BT were distributed in 4 statistical groups: 0—2,
3—5, 6—10, and greater than 10. There were no differences in % of
functioning transplants at 1 year, or serum Cr, or number of rejects.
There was however, correlation between BT and cytotoxic levels (P <
0.05). No correlations were observed between HLA compatibilities,
transplant survival, and rejection frequency, when analyzed by Locus
A, B, and DR, or in combinations. The 7 retransplants were functioning
at 1—18 months without any rejection episodes. Transplant survival at 1
year was 84%, with 1% mortality:
Incompatibilities % of Patients
A B DR
0 17.5 20.8 67.0
1 40.6 38.4 23.0
2 41.7 40.6 9.8
Conclusions. The data suggest that patients to be treated with CsA
should receive as few BT as possible and that the HLA incompatibility
at 1 year did not significantly affect transplant survival.
Does cyclosporine (CsA) increase acute tubular necrosis (ATN) inci-
dence and prolong recovery in cadaver renal transplants (CRT). M.
Gonzalez-Molina, M. Cabello, M.A. Frutos, P. Aranda, B. Ramos, E.
Lopez de Novales, S. Nefrologla. Hospital Regional Carlos Haya.
Malaga, Spain. It is held that CsA aggravates and prolongs ATN. This
study evaluated 179 CRT (91 with CsA from day 1, and 88 with
azathioprine (Az)). Incidence of ATN in 2 groups was: CsA 57 (62.2%);
Az 65 (73.8%). Initial dose of CsA was 14/mg/kg/day but blood level
monitoring permitted progressive dosage decrease to less than normal
which maintaining average week 1 levels at, or above, upper limit of
accepted range: 818 530 ng/ml (ATN), and 987 412 ng/ml (without
ATN) (P = NS). Index of ATN prolongation was no. of dialyses.
Az-ATN CsA-ATN
CsA-No
ATN
No. of patients
Age recip. years
Age donor years
Warm isch m
Rewarm isch m
Cold isch h
No. dialyses
65
36.5 10.5
29.0 13.2
4 5,9a
—
28.5 6.9
4.9 3.1
57
33 11.6
31 16.2
2.5 3,6
54 38.5a
26 6.5
5.1 2.9
34
37.7 11.9
22.8 12.9
2.2 1.8
40.3 11.0
25.5 5.6
a P significance < 0.05
In cases treated with CsA, the significant factor (P < 0.05) in presence
of ATN was rewarm isch. Plasma creatinine was higher for CsA with
ATN in month 1 (P < 0.001) but difference disappeared thereafter and
at 1 yr 1.75 0.8 vs. 2.09 2.2 mg/dl(P =NS). Transplant survival of
CsA group was 91% per year. Conclusions: CsA does not increase
incidence of ATN in dosage used, nor does it modify recovery. The
presence of ATN does not affect subsequent renal function.
Acute renal failure (ARF) and hyperkalemia after heart transplantation
and cyclosporine A (CyA) therapy. P. Errasti, J. Herreros, R. Arcas, J.
Diez, A. Purroy, Division of Cardiovascular Surgery and Nephrology.
University Clinic, Pamplona, Spain. Although CyA has improved the
results of heart transplantation, nephrotoxicity with occasional postop-
erative oliguric ARF requiring dialysis and hyperkalemia are recognized
side effects. We report these complications in 10 consecutive heart
transplants, performed from July 1984 through August 1986. The
immunosuppressive protocol consisted of CyA 15 mg/kg/daily given
before the operation, and prednisone (P) I mg/kg/daily. After the
operation two patients, (1, male, 36 years old and 2, female of 41 years),
experienced an oliguric ARF. The first required peritoneal dialysis
during the 10 first days followed by hemodialysis for another 13 days (8
sessions). The second patient required hemodialysis during the first six
days (4 sessions). Reversal of the oliguria was started after suspension
or reduction of CyA dose, and addition of azathioprine (AZA) in the
first patient and AZA plus RATG in the second. A third patient
experienced a transient postoperative renal dysfunction with progres-
sive increase of creatinine from 1 to 2.4 mg% on the fourth day after the
operation, and was spontaneously reversed with decrease CyA dose
and addition of AZA. No death could be attributed to renal failure.
Another two patients developed severe hyperkalemia (more than 6
mEq/liter) without renal failure. They were initially treated with furo-
semide and oral potassium binding resin (30—100 g/daily). For persistent
hyperkalemia, a mineralocorticoid (fludocortisone acetate 0.1 mg once
daily) was used and serum potassium fell within three days to normal
level. This suggests that hypoaldosteronism may play a role in the
etiology of hyperkalemia associated with CyA therapy. Seven of the 10
heart transplants are functioning nowdays with a follow—up from 2 to 23
months (mean = 8.2 months). One patient died during surgery and two
more patients after 35 days and 12 hemorrhaged. Four patients are in
treatment with CyA + P and three patients with triple therapy (CyA +
P + AZA). The high rate of ARF and hyperkalemia apparently related
to the relatively initial high dose of CyA (15 mg/kg/day), a fact already
reported repeatedly in the literature, has prompted us to change the
immunosuppressive proctocol, decreasing the CyA dose to 8 mg/kg/day
and adding AZA (1.5—2 mg/kg/day) in order to reduce the incidence of
renal dysfunctions.
Statistical analysis of 174 first consecutive cadaver renal transplants
(CRT) performed during 1976 to 1986. J.E. Robles, P. Errasti, J.
Zudaire, J. Diez, J.M. Berian, A. Purroy, DivisiOn of Nephrology and
Urology, University Clinic, Pamplona, Spain. We analyzed the results
of a retrospective study of 174 first CRT (males = 1 l3p-64.9% and
females = 6lp-35.l%) with a mean age of 35 8 (range 47 years), and
a follow—up from two months to 10 years. BMDP-Statistical software
UCLA Program was used with 113 variables potentially influential in
graft outcome (age and sex of the donor and recipient, etiology of renal
disease, ABO, Rh, HLA matching, cytotoxic antibodies, pre and
post-transplants transfusions, etc.). The actuarial patient survival (PS)
and graft—survival (OS) rates were calculated with the product—limit
method of Kaplan—Meier. For testing the equality of survival curves
(GS), the Mantel—Cox test was used. P values under 0.05 were
considered to be significant. Results:
lyr 2yrs 3yrs Syrs
N=96 N=60 N=41 N=18
PS(%±ES)
GS(%±ES)
92±2
76±3
92±2
69±4
91±2
66±4
88±3
60±6
Only three of the 113 variables, potentially influential in GS were
statistically significant: (1.) immediate graft function (IGF) versus
delayed graft function (delayed graft function was defined as the need
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for hemodialysis during the first week after transplantation); (2.)
Diuresis during the first 24 hours after renal artery clamp release; (3.)
The need for transfusions during the first 10 days after transplantation.
Variables
Patients
(N/%)
1-
su
year graft
rvival (%)
I. LGF
Yes 90/52 89 P < 0.0001
No 84/48 61
2. 24 h. diuresis (liters)
>10 30/18 90 P < 0.02
5—10 57/34 77.2
1—5 63/37.5 59
<1 18/10.5 50
3. Post-transplant transfusions
Yes 91/53 68 P < 0.04
No 82/47 86
We also report the results related with the other variables studied, the
etiology of graft—lost and death of the patients.
Enhanced red—cell lithium—sodium countertransport activity in patients
with liver cirrhosis and ascites. J. DIez, J.I. Varela, F. Indart, A.
Purroy, J. Prieto, Div. of Nephrology, Dept. of Medicine, University
Clinic, Pamplona, Spain. Increased renal Na4 reabsorption is a com-
mon complication of liver cirrhosis. The responsible mechanisms
remain incompletely understood. On the other hand, it has been
proposed that red cell Li4:Na4 countertransport (Li':Na4CT) may
also exchange external Na4 for internal H', and that this exchange is
analogous to the countertransport of these two ions at the luminal side
of cells from proximal renal tubule. We, thus, have studied Li':Na4 CT
activity (Li4:Na' CTa) in red cells from 16 patients with liver cirrhosis
and ascites under a restricted Na4 diet (40 mmol X day) during 4
days. None of the patients had renal failure. All patients were free of
pharmacological treatment. As compared to 9 healthy controls under a
restricted Na4 diet, patients showed an increased Li':Na' CTa (0.022
0.005 vs. 0.014 0.001, x hr', mean SEM, P < 0.005). By
analyzing individually Li4:Na4 CTa two subgroups of patients
emerged: those (N = 5)with the higher Li4:Na' CTa (0.027 0.010, X
hr1) and the lesser natriuresis (0.004 0,001 mmol x min') and those
(N = 11) with a lower Li':Na4 CTa (0.019 0.001, x hr') and a
higher natriuresis (0.046 0.006 mmol x min'). These results indicate
that hyperactivity of Li' :Na4 countertransport is present in red cells
from patients with liver cirrhosis and ascites. If cation countertransport
in red cells were a marker for activity of Na4 :H4 exchange in the
proximal tubule, our results would suggest that enhanced proximal
tubular Na4 reabsorption may be of pathogenic importance in the Na4
retaining process of liver cirrhosis,
Effects of atriopeptides and cyclic GMP on calcium dependent potas-
slum efflux in human red cells. N. Esparza, J. DIez-Tejeiro, L. Yap, F.
Maduell, P. Errasti, A. Purroy, Div. of Nephrology, University Clinic,
Pamplona, Spain. Norepinephrine (NE) and angiotensin II (A II) cause
vascular contraction by increasing cytosolic Ca24. After application of
atriopeptides, vascular preparations are resistant to subsequent stimu-
lation by NE and A II. The action mechanism of atriopeptides involved
in the above effect seems to involve changes in Ca24 fluxes. In addition,
the stimulation of guanylate—cyclase activity by atriopeptides might be
responsible for such a change in Ca24 transport. We have investigated
here the interaction of rat atriopeptides I and II (AP I and AP II,
respectively) and cyclic GMP (cGMP) with Ca4-dependent, K4 efflux
in human red cells. Ca2-dependent, K efflux was measured by adding
the Ca2 ionophore A23l87 at different concentrations to an efflux
medium which did not contain K. The dose—response curves of K
efflux as a function of A23 187 concentration were modified by addition
of physiologic concentrations of API and API!. In fact, an inhibition of
35 5% of K4 efflux was observed at concentrations of A23 187 below
1 sM. This effect was not observed at higher concentrations of Ca2
ionophore. In experiments performed at a constant concentration of
A23187 of 1 LM, the IC50 of AP I and API! were about 10-10 M. A
similar inhibition of Ca24-dependent K4 efflux was observed with
cGMP at concentrations ranging between 1 and 8 m. Our results
suggest that atriopeptides and cGMP are able to counterbalance a slight
increase in cytosolic free Ca24 content in human red cells.
Asymmetric septal hypertrophy (ASH) in dialysis patients: Clinical
significance and echocardiographic evolution. 0. Ortega Marcos, J.
Martinez Ara, F. Garcia Fernandez, A. Rodriguez—Carmona, A. Sanz,
L. Sanchez Sicilia, I.C.N., Servicios de Nefrologla y CardiologIa,
Hospital La Paz, Madrid, Spain. A higher incidence of ASH, with a
worse tolerance to conventional hemodialysis has been demonstrated in
patients undergoing long—term hemodialysis treatment than in general
population. To evaluate the incidence of ASH, its clinical significance
and evolution in uremic patients, we divided our 65 dialysis patients
into three groups based on their M-mode echocardiographic findings:
Group I, patients with ASH (N = 20; a ratio of the thickness of the
interventricular septum to the posterior ventricular wall greater than
1.3). Group II, patients with concentric ventricular hypertrophy(CVH)(N = 27; thickness of the septum = the ventricular wall > 12 mm).
Group III, patients with normal heart (N = 18). The incidence of ASH
was 31%. G I and G II patients had a higher average age, and also more
hypertensive patients were found than in 0 III (P < 0.05). No statistical
differences were found in the analytical data (BUN, serum creatinine,
Hcto, Hb, cholesterol, triglycerides) but in the alkaline phosphatase
that was higher in G I and 0 II (P <0.01); a simultaneous increase in
the PTH was not observed. The patients with ASH had a worse
tolerance to hemodialysis (with a greater frequency of hypotension) and
a greater incidence of angor and arrthythmia during dialysis that
patients with CVH and normal heart as is shown in the Table:
HDtolerancea
0!
0.8
GIL
14b
Gill
l.7c
Angor% 50 185b 5.5c
Arrhytmia % 40 18.8 11.5
a Bad = 0, Regular = 1, Good = 2
b P < 0.02 G I vs. 0 II
P < 0.001 G I vs. 0 III
Four patients with ASH received digitalis therapy, probably because of
the occasional presence of congestive heart failure. Its suppression
improved their tolerance to hemodialysis and decreased their episodes
of angor during dialysis. M-mode echocardiographic course was fol-
lowed in 14 out of 20 patients with ASH. Eleven patients (78%)
developed a CVH in the following years (1—3 yrs). We conclude that the
incidence of ASH is rather high in hemodialysis patients. The presence
of hypotension, angor and arrhythmia during hemodialysis, in addition
to the auscultation of a systolic heart murmur could lead to the
midsdiagnosis of pericarditis. The ASH could be the initial step of the
CVH. As digitalis can worsen the symptoms and the hemodialysis
behavior of ASH, it should not be used in these patients.
Dialysis eosinophilia (DE): Association with IgE specific anti-etilen
oxide (IgE anti-ETO). J. Aranzabal, R, Saracho, I. Gainza, J.
Amenabar, J. Martinez, M. Urra, I. Lampreabe, Servicio de
Nefrologla, Hospital de Cruces, Baracaldo—Vizcaya, Spain. Thirty
chronic hemodialysis patients, 60% males, average age of 47 years and
mean of time from start hemodialysis 67 months, were divided into
three groups with regard to eosinophiie count in peripheral blood.
Seven patients were included into the persistent DE group (PED), 10
into the intermittent DE group (IDE) and the remainder, 13 patients,
were the control group (CG), because these patients did not have DE
during the study period. In all subjects, total IgE (turbidometry) and
specific IgE anti-ETO (RAST) were measured in addition to routine
biochemical and hematological parameters. There were no statistical
differences, such as age, sex, time in dialysis, dialyzer and membranes.
Using analysis of variance, it was proved that the EDP group had a total
IgE and LgE anti-ETO titles greater than the IDE group, and those of
IDE greater than GC (P < 0.001). In "a posteriori" comparison, the
fundamental difference was between PED and the other two groups
togehter (P < 0.01), without differences between IDE and GC. We
found a correlation coefficient r = 0.71 between eosinophile number and
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IgE anti-ETO titles (P < 0.001). This supports an association between
specific IgE anti-ETO antibodies and ED.
Adenosine and intracellular calcium. P.G, Cosmes, A. Refoyo, E. del
Barrio, 1. Ramos, A.M. Castro, J.F. Macias, Hospital "Virgen de la
Vega" and University Hospital, Salamanca, Spain. Renal vasocon-
striction (Vc), adenosjne (Ado)-mediated, is related to Ca transmem-
brane movements. Trifluoperazine (Tfp) blocks Ca + release from the
cytosol via calcium—calmoduline complex blockade. The aim of this
study was to evaluate the influence of intracellular Ca + and calcium
channel blockade on the Ado-induced renal hemodynamics. Seven dogs
were intrarenally infused with 0.2 M Ado for 10 minutes (B.C.). Then
an intrarenal infusion of calcium was started and maintained until the
same magnitude of Vc was reached. Next a 140 M i.r. infusion of Tfp
was started; 45 mm later, Ado was added to Tfp for 10 mm (Tfp + Ado);
30 mm later, calcium was added to Tpf (Tpf + Ca). In two additional
dogs, verapamil (Vp), 10 g/kg/min, was i.r. infused at the midpoint of
Tfp + Ado and Tfp + Ca. RBF and BP were continuously recorded. In
B.C., RBF was 108 mI/mm; ADo provoked a Vc to 4 mI/mm; 10 mm
later, R.B.F. was 109 mI/mm; Ado withdrawal produced a rebound (R)
to 145 mI/mm. Ca produced a gradual reduction of RBF similar to Ado;
R was not seen when i.r. Ca infusion was discontinued. Tfp alone did
not alter RBF. In Tfp + Ado, a prompt Vc to 47 ml/min was induced
and maintained at this level until Ado was retired; R was not seen. Tfp
+ Ado behaved similarly to Tfp + Ca. Vp in Tfp + Ado inmediately
reverted Vc from 52 to 180 mI/mm. Vp in Tfp + Ado produced a similar
effect following i.r. calcium infusion withdrawal. We conclude that
renal Vc promoted by i.r. infusion of Ado is related to intracellular
Ca increase, probably due to the entry of Ca into the contractile
renal cells.
Acute vascular rejection (AVR) treated with plasmapheresis (PF):
Relationship between morphological changes and therapeuthic response.
A. Franco, F. Anaya, E. Niembro, F. Ahijado, J. Luño, F. Valder-
rábano, Hospital Provincial, Madrid. Corticoresistent AVR has been
treated with PF in our Center from January 1983. Forty—nine patients
out of 150 have submitted to this procedure. Trying to find a relation-
ship between histological changes before treatment and the clinical
response to it, we have studied 30 patients with a previous renal biopsy.
We classified vascular lesions in 5 groups: I. Acute active endovascu-
litis; II. subacute lesions; III. residual changes; IV. type land II lesions
superimposed over chronic changes; V. unclassifiable. Treatment con-
sisted of one PF daily session during 6 consecutive days. A cellulose
diacetate filter was used to remove 40 plasma ml/kg per session, which
were replaced by the same quantity of pasteurized plasma proteins.
Results are shown in this Table:
I II III IV V
Cr
(mg/dl)
Pre-FP
Cp,
(mgldl)
Post-PF
Patients 16 1 6 6 1
Response 14 1 0 0 0 6.7 1.8
No response 2 0 6 6 1 5.8 HD
Patients with response to PF showed a stabilization of their renal
function longer than 6 months. No responders re-entered in HD before
15 days from the end of treatment. Transient hypofibrinogenemia was
commonly observed. There was one death without a clear explanation.
PF is an elective way of treatment in corticoresistant AVR with acute or
subacute lesions. Nevertheless its efficacy is doubtful in the case of
chronic injury.
Complications and long—term renal function in kidney donors. J.J.
Plaza, H. Calvete, G. De Arriba, L. Cabrera, L. Hernando, Fundacion
Jiménez Diaz, Servicio de Nefrologia, Madrid, Spain. We assessed the
complications and renal function outcome of 75 kidney, living donors
immediately (20 6 days) and in the long—term period (6 months to 15
years) after uninephrectomy ( 4.8 3.7 years). There was not
postoperative or late mortality related to nephrectomy, and the surgical
complication rate, although apparently high (55 complications/75 pa-
tients), was not serious. The 3 weeks and 4.98 years postunine-
phrectomy percentages of predonation creatinine clearance were 78%
and 84%, respectively (P < 0.05), except in donors over 60 years of age
(16 cases) in whom these late increases did not happen. Nineteen
donors in whom the mean follow up period after surgery was over 7
years ( 9.16 2.2 years) (range 7 to 15 years) showed similar decrease
of Ccr percentage than the general group. The 24-hr urine protein
excretion increased over the normal range in four donors (333 to 500
mg/24 hr) and five other (6.6%) became hypertensive (diastolic >95 mm
Hg), although all except one of them were controlled with only diet and
weight measures. In conclusion, this study of kidney donors shows no
adverse effects after many years of compensatory hyperfiltration, which
contradicts the living kidney transplantation policy.
Pharmacological modulation of adriamycin—induced nephropathy. A.
Robles, J. Egido, A. OrtIz, R. de Nicolas, E. Gonzalez, F. Mampaso,
L. Hernando, Fundación Jiménez Diaz, Hospital RamOn y Cajal,
Madrid, Spain. In a model of nephrotic syndrome induced by a single
intravenous injection of adriamycin we studied the effect of steroids,
heparin and two specific PAF-antagonists (BN 52021 and tnazoloben-
zodiazepines) on the appearance of proteinuria and on the histological
changes. The treatments were administered from day 0 to day 28 after
adriamycin injection. All animals injected with adriamycin were heavily
proteinuric on day 21(372 53 mg/24 hr). Steroids did not have any
effect on the proteinuria (283 183). Heparin induced a moderate
diminution of the proteinuria (221 64). By contrast, rats receiving
PAF antagonists either did not present proteinuna or only in very low
amounts (BN 52021 group, 23 2; alprazolam, 5 2; triazolam 16 5;
P < 0.0005). Electron microscopy examination of kidneys in rats
injected with adriamycin showed alterations of glomerular epithelial
cells with fusion of foot processes, while in animals treated with PAF
antagonists no abnormalities in these cells were observed. These data
suggest that PAF might be involved in the pathogenesis of proteinuria of
experimental nephrosis and that the employment of PAF antagonists
could be an alternative in the treatment of human nephropathies with a
similar clinicohistological picture.
Detection of shared idiotypes in kidneys of patients with IgA nephrop-
athy. J. Gonzólez Cabrero, J. Egido, J. Sancho, F. Mampaso, C.
Rivas. Fundación Jiménez DIaz and Hospital Ramon y Cajal, Madrid,
Spain. It has been postulated that anti-idiotypic antibodies would
participate in the in vivo immune complexes (IC) formation, competing
with food antigens for binding sites of the idiotypic antibodies. We have
demonstrated that IC from patients with IgA nephropathy present
fluctuations after the ingestion of a large amount of proteins; and also
we have recently isolated idiotypic antibodies against bovine serum
albumin (BSA) from a patient with this renal disease (Clin Exp immu-
nol, in press). The frequency of serum shared idiotypes was signifi-
cantly higher in patients with IgA-IC (67.5%) and these idiotypes were
present in the 62% of the subjects with hematuria. In this work we
studied the presence of cross—reactive idiotypes in kidneys of patients
with IgA nephropathy. Renal biopsy tissue of 30 patients were incu-
bated with an anti-idiotypic antibody raised in rabbits, and further with
fluorescein—or peroxidase—conjugated anti-rabbit immunoglobulins. In
the 23% of the patients the presence of idiotypic antibodies against BSA
was detected within the mesangium and paramesangial areas, with a
similar granular pattern distribution to that of IgA. The adsorbed
anti-idiotypic serum completely abolished the staining. In the patient
with IgA nephropathy in whom the BSA-antibody idiotypes were
isolated, these shared idiotypes were also demonstrated at the kidney
level. These results suggest that the IC containing idiotypes—anti-
idiotypes might play a role in the pathogenesis of this disease.
IgA immune regulation by peripheral blood and tonsil lymphocytes
from IgA nephropathy patients. R. Garcia Hoyo, L. Lozano, R. de
Nicolas, J. Egido, L. Hernando, Department of Nephrology,
FundaciOn Jiménez Diaz, Madrid, Spain. In recent years several
investigators have shown the existence of IgA immune abnormalities in
patients with IgA nephropathy, but conflicting results exist yet, These
differences could be due to the different cithcal activity, to the possible
heterogeneity of the disease, or to the employment of peripheral blood
lymphocytes (PBL) rather than mucosal cells (tonsil lymphocytes). We
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have studied simultaneously the immune regulation of IgA by cells of
both origins in 11 patients with IgA nephropathy. In unstimulated
cultures, PBL from patients produced, as average, significantly larger
amount of IgA, but not IgG and 1gM, than those from controls. There
were no differences in the in vitro IgA synthesis from tonsil lympho-
cytes, but when stimulated with PWM no increased IgA production was
observed. The polymeric IgA synthesis by whole cell populations as
well as the IgA synthesis from enriched B cells were higher in PBL and
tonsil lymphocytes from patients than from controls. We also observed
an inversion in the ratio of IgA versus IgG bearing tonsil lymphocytes
from patients. When blood T cells from patients or controls were
co-cultured with allogeneic blood B cells, there was no significant
difference in the mean IgA unstimulated production. By contrast, tonsil
T cells from patients were significantly more efficient than control ones
in the synthesis of IgA, when co-cultured either with blood or tonsil B
cells from controls. These data suggest that lymphocytes obtained from
tonsils of patients with IgA nephropathy present more intensive abnor-
malities of the IgA synthesis regulation than PBL, and therefore they
are more suitable in order to study the mechanisms of the abnormal IgA
production in this disease.
Immunological studies in six familial IgA nephropathies. L. Lozano, R.
Garcia Hoyo, R. Blasco, R. de Nicolas, J. Egido, L. Hernando,
Servicio de Nefrologia, Fundacidn Jiménez Diaz, Madrid, Spain. Data
suggests that IgA nephropathy is a genetically determined disease: the
occurrence of the disease in siblings, the occasional association to HLA
antigens and the existence of IgA immune abnormalities in healthy
relatives. We assembled 6 families, each one with at least two members
with biopsy proven or strongly suspected IgA nephropathy (12 patients
and 21 relatives). In 5 out of 6 families, the two patients were siblings.
In 4 out of 6 families, one out of the two patients was in end—stage renal
failure, All the patients but one have presented recurrent episodes of
macroscopic hematuria. As a mean both patients and relatives present,
related to controls, an increased spontaneous and stimulated in vitro
IgA synthesis, percentage of polymeric IgA synthetizing lymphocytes
and of IgA bearing cells and OKT4/OKT8 ratio. Patients differ from
relatives chiefly in the % of polymeric IgA producing and IgA bearing
cells and in the OKT4/OKT8 ratio, that were higher in patients than in
relatives and higher in relatives than in controls. Nine out of 12 patients,
6 out of 12 brothers and sisters and 4 out of 9 parents present at least 3
abnormal immune probes. Although the number of families typed for
HLA antigens was reduced there was no correlation between DR4 and
these IgA abnormalities. The existence of these abnormalities com-
monly seen both in patients and in asymptomatic family members raises
the possibility that besides the genetic background of "high IgA
responder" subjects, other unknown factors are necessary to mediate
tissue damage and disease expression.
Role of calcium in the concentration Induced by angiotensin II (All) on
cultured glomerular mesangial cells. V. Barrio, A. Olivera, L. Hernan-
do, J.M. LOpez Novoa, D. Rodriguez Puyol, Fundación Jiménez DIaz,
Madrid, Spain. Mesangial cells were obtained by single differential
culture of mechanically isolated rat glomeruli. Mesangial cells were
incubated with the several substances assayed for 45 mm into culture
flasks, and serial microphotographs were taken using a phase contrast
microscope. Planar cell area (PCA) was calculated for the photographs
using a computerized technique. PCA was not modified by the 45 mm
incubation. In these circumstances All (10 M) induced a progressive
decrease in PCA that reached a 30% of basal values after 45 mm of
incubation. Preincubation with verapamil (l0 as) before All partially
blocked the effect of All (PCA decreased by a 19%) whereas the
preincubation with TMB-8, an antagonist of the intracellular calcium
release had a significantly higher blocking effect (PCA increased by an
11%). Preincubation with both verapamil and TMB-8 completely
blocked the contractile effect of All preincubation with atrial natnuretic
peptide (ANP). These results suggest that All is able to contract
cultured mesangial cells by a calcium—dependent mechanism. This
effect seems to depend on both extracellular calcium entry and release
from intracellular stores, being this last mechanism quantitatively more
important. ANP blocks All-induced contraction. The effect on mesan-
gial cell contraction could be a mechanism involved in the regulation of
GFR by All and ANP.
Ilemodialysis (lID) corrects the activations in catlonic fluxes In eryth-
rocytes: Evidence of two populations. R.J. Bosch, N. Hernando, J.M.
LOpez Novoa, S. Casado, Department of Nephrology, FundaciOn
Jiménez DIaz, Madrid, Spain. The purpose of this study has been to
define the alterations in cationic fluxes and intracellular Na in uremic
patients on hemodialysis. Na fluxes were studied in 21 uremic patients
before and after HD and in 10 normal subjects. All were normotensive
and saline was not administered during HD. There was a weight loss
during HD of 3.1 0.2 kg. According with the results, patients could be
divided in two groups. Group 1: 6 patients. These patients showed,
compared with controls, a decrease in ouabain—inhibible Na flux (Na
pump: 1539 255 vs. 2231 303 jsmol/liter. hr; P < 0.05) and
furosemide—inhibible Na flux (cotransport: 19 10 vs. 143 25; P <
0.02). No differences were observed in contratransport or intracellular
sodium. HD corrected all the changes and no significant differences
with control data were observed. Group 2: 15 patients. These patients
showed no significant differences in the sodium pump (2324 102
smol/liter. hr); cotransport nor contratransport but an increase in
intracellular sodium (9.25 0.82 vs 6.9 7.6 mEq/liter). After HD no
differences in transport systems or in intracellular Na were observed.
These data suggest the existence of 2 groups of uremic patients. In the
first one, data suggest the existence of a dialyzable factor that inhibits
Na pump. In the second group, this factor would be counteracted by an
increase in intracelluar sodium concentration.
Atrial natriuretic peptide (ANP) inhibits glomerular contraction in-
duced by angiotensin II (All) and platelet activating factor (PAY). V.
Barrio, G. de Arriba, D. Rodriguez Puyol, L. Hernando, J.M. LOpez
Novoa, FundaciOn Jiménez DIaz, Madrid, Spain. The purpose of this
work has been to study the effect of ANP on the contraction induced by
All and PAF in isolated rat glomeruli. Glomeruli were isolated by a
sieving technique and incubated at room temperature with either All
(l0 M), PAF (10-6 M), All + ANP, or PAF + ANP. Before and 20
mm after adding the reactives, glomeruli were photographed, and then
glomerular cross—sectional area (GCSA) was measured by a computer-
ized technique. Results of GCSA (m2 x 10—8) are:
0 mm. 20 mm.
Control 1.63 0.03 (N = 74) 1.60 0.03 (N = 65)
All 1.61 0.04 (N = 32) 1.45 0.03 (N = 65)
PAF 1.65 0.03 (N = 4) 1.49 0.02 (N = 77)
ANP 1.62 0.05 (N = 38) 1.60 0.03 (N = 62)
All + ANP 1.60 0.03 (N = 78) 1.59 0.03 (N = 61)
PAF + ANP 1.57 0.03(N = 48) 1.64 0.04(N = 44)
Data are mean seas; (N) = number of glomeruli measured
aP < 0.05 vs. time 0.
ANP per se does not modify GCSA, but blocks glomerular contraction
induced by both All and PAF. These results suggest the action of ANP
on GFR and natriuresis could be mediated by increments of GCSA and,
subsequently, of the ultrafiltration coefficient.
Role of the atrlal natriuretlc peptide (ANP) in the renal water and
sodium handling impairment of experimental cirrhosis in rats. A.
Olivera, D. Rodriguez Puyol, J. Gutkowska, I. Millas, G. de Arriba, L.
Hernando, f.M. Lopez Novoa, FundaciOn Jiménez DIaz, Madrid,
Spain, and Clinical Research Institute, Montreal, Canada. This study
was designed to clarify the role of ANP in the renal dysfunction shown
by rats with CC14/phenobarbital—induced cirrhosis of the liver (LC).
Plasma levels of ANP were measured by RIA and renal function by
clearance studies. Plasma ANP was higher in LC than in control (C) rats
both in basal conditions (75 7 vs. 38 8 pg/mI, respectively; P <
0.05) and after an extracellular volume expansion (3% body weight; 135
15 vs. 60 12 pg/mI). In both groups of animals, the increase of ANP
plasma concentration after volume expansion was significant. The i.v.
infusion of a bolus of ANP (1 sg) disclosed the following changes in
renal function:
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UV mi/mm UNa p.Eq/min FG mi/mm
C
Basal 6.0 1.6 0.3 0.1 1.3 0.4
ANP 91.0 21.0 7.3 l.9 2.7 Ø7
LC
Basal 6.2 1.0 0.1 Ol' 1.3 0.2
ANP 37.6 74a,b 13 04a,b 2.4 0.5
a p < 0.05 vs. basalb <0.05 vs. C
These results suggest that ANP does not seem to be involved in the
renal sodium and water retention observed in experimental liver cirrho-
sis. In addition, a blockade exists of the biological action of this peptide
in rats with cirrhosis of the liver.
The "stone clinic" effect in patients with idiopathic calcium
urolithiasis. D. Arias, A. Rapado, E. Garcia de Ia Peña, C. Caycho,
Internal Medicine and Urology Services, Fundac ion Jimenez Diaz,
Madrid, Spain. The "stone clinic effect" is defined as the metabolic
activity control of renal lithiasis (R.L.) under the effect of high fluid
intake and low calcium, protein, purines, oxalate and salt intake
without concomitant drug therapy. To evaluate the extent of the "stone
clinic effect" and to determinate if the metabolic activity of urolithiasis
was related to fluid intake, 46 patients were followed during 7.4 years
(range: 3 to 14) with exclusion of secondary R.L. Fourteen patients had
no metabolic abnormalities; nine had hypercalciuna; ten had hyperuri-
cosuria and thirteen had both. To all the patients a high fluid intake (>
2000 mi/day) and dietary restriction was recommended. We define good
control (GC) a metabolic and radiological R.L. inactivity. Good treat-
ment (GT) confirms adhesion to therapeutic recommendations. BC
means bad control and BT, bad treatment. Results. Thirty—four patients
(74%) have GC. No influence in hypercalciunalhyperuncosuria was
seen. All of the GC patients have a significant increase in urinary
volume output as compared to pretreatment or BC patients (P < 0.05).
No patient with GT has BC, and all the patients with GC have GT. In
spite of BC 13 patients were metabolically inactive during follow—up.
Conclusions. In the majority of R.L. patients, high fluid intake and
dietary recommendations alone constitute adequate therapy. A signifi-
cantly higher 24-hr urine volume in patients metabolically inactive at
follow—up supports the treatment of that drug therapy only until new
stone formation has been evaluated.
Hypocitraturia: another cause of oxalocalcic renal lithiasis. C. Grant,
A. Rapado, E. Garcia de la Peña, C. de Ia Piedra. Unidad Metabolica,
Fundacion Jimenez Diaz, Madrid, Spain. In the etiological classifica-
tion of renal lithiasis (R.L.) there are an imporant number of patients
with unknown causes. Recently has been described the role of urinary
citrate in calcium oxalate/calcium phosphate precipitation; the high
incidence of hypocitraturia in R.L. and the prevention of renal stones
formation after chronic administration of citrate salts. We have selected
61 R.L. patients seen for the first time and without previous drug
treatment at least for three months. In all the cases a secondary cause
was excluded, including renal tubular acidosis, urinary infection or
urinary pH > 6.9. Citric acid was measured with an enzymatic method
(Normal values: >320 mg/24 hr; >0.200 urinary citrate/creatinine ratio).
Results. In 24 cases we found hypocitraturia (mean: 161.4 90 mg/24h;
range: 35 to 311). In nine patients there were other metabolic abnor-
malities. Hypocitraturia was presented in 27.4% of idiopathic R.L.
patients. Conclusions. In patients with R.L. there is an important
subgroup with hypocitraturia; a possible etiological factor in saturation,
nucleation and aggregation of calcium salts in urine. In patients with
idiopathic R.L., hypocitraturia may represent a physiopathological
cause which must be assessed in order to define and treat as profilaxis
of renal stone formation.
Hyperalbuminemia and parathyroid hormone(PTH) release: Clinical
and experimental evaluation. J.B. Cannata, M.C. Diaz de Greñu, M.T.
Allende, A.L.M. De Francisco, J. Lamas, J. Herrera, B.J.R. Junor,
Hospital General de Asturias, Facultad de Medicina de Oviedo,
Asturias, Spain. Centro Marquees de Valdecilla, Santander, Spain,
Renal Unit, Western Infirmary, Glasgow, Scotland, United Kingdom.
Nowadays there is enough evidence that aluminium (Al) could suppress
PTH release either through direct or indirect mechanisms. The aim of
this study was to evaluate clinical and experimentally PTH response to
hyperaibuminemia. Clinical experience. We studied a total number of
40 hemodialysis (HD) patients with several degrees of hyperparathy-
roidism in whom we evaluated in two steps if the sharp serum Al
increase induced by the desferrioxamine (DFO) could acutely modify
the PTH release. First step: (I) We infused (Inf) 50 to 100 mg of DFO
at the end of HD (1), measuring serum Ca Al, and PTH (Intact
hormone and C terminal) in A, B, C and D (Figure). In the second step
(2) we followed the same protocol but infusing DFO 24 hours afer HD
once serum Ca reached more stable values.
(I)AHD B—24 hrs—
(1)DFO ml
(II)CHD D
(2)DFO INF
Results. In both steps, 48 hrs after DFO infusion (C), serum Al had a
significant increase (from 4.2 to 22.8 mol/liter), however, the intact
PTH did not show any important change (from 52.7 to 58.6 ng/liter)
despite the same assay was able to show acute and significant changes
following the intra- and interdialytic serum Ca variations. The C
terminal PTH did not show any change throughout the study. Experi-
mental experience. We studied 35 male, adults Wistar rats with normal
renal function divided in three groups. Group I: Controls, Group II:
Endogenous hyperparathyroidism + acute Al intoxication (3 mg/intra-
peritoneally (ip) during three days), Group III: Chronic Al intoxication
(total dose: 90 mg ip in 2.5 months). In all groups we induced acute
hypocalcemia with EGTA, studying the PTH levels (N-Tact and
rat-PTH) at 1, 2 and 10 minutes. We observed in all three groups a
significant PTH increase (both assays) within the first 2 minutes,
without significant differences between controls and acute and chronic
Al-intoxicated rats. In summary; in both clinical and experimental
experiences, we did not observe any direct effect of the high Al levels
on the acute PTH response. In the clinical study this lack of effect could be
due to the fact that Al-DFO as a complex can not act on PTH release.
